

EXHIBIT H –
DECLARATION OF
DANIEL E.
BUFFINGTON

AARON D. FORD
Attorney General
D. Randall Gilmer (Bar No. 14001)
Chief Deputy Attorney General
State of Nevada
Office of the Attorney Generals
555 E. Washington Ave., Ste. 3900
Las Vegas, Nevada 89101
Telephone: (702) 486-3427
Facsimile: (702) 486-3773
Email: DGilmer@ag.nv.gov

*Attorneys for Defendants Daniels,
Wickham, Gittere, Reubart, Drummond,
Minev, Green and Fox (NDOC Defendants)*

UNITED STATES DISTRICT COURT

DISTRICT OF NEVADA

ZANE M. FLOYD,

Plaintiff,

v.

CHARLES DANIELS, DIRECTOR, NEVADA
DEPARTMENT OF CORRECTIONS, ET AL.,
Defendants.

Case No. 3:21-cv-00176-RFB-CLB

**DECLARATION OF
DR DANIEL E. BUFFINGTON**

I, Dr. Daniel E. Buffington, hereby declare based on personal knowledge and/or information and belief, that the following assertions are true.

Introduction:

1. The purpose of this Affidavit is to respond to speculative statements made by the Plaintiff, Zane Floyd, concerning the State of Nevada's lethal injection manual (aka Execution Manual) and their concerns as to the utility and effectiveness of the pharmaceutical substances included in the State's 4-drug and 3-

drug regimens. It is my opinion that the pharmaceutical substances, in the forms, dosages, routes of administration, manner and timing of administration will certainly result in the death of an inmate.

Background:

2. I am a Clinical Pharmacologist and Toxicologist. I have a Doctor of Pharmacy degree (PharmD) degree and Master of Business Administration (MBA) degree from Mercer University. I also completed a post graduate Residency and Fellowship from Emory University. I have been licensed and practiced in the States of Florida and Georgia since 1987. I have a private Clinical Pharmacology specialty practice located at 6285 E. Fowler Ave, Tampa, Florida 33617. I am on the faculty at the University of South Florida, Colleges of Medicine and Pharmacy and have numerous faculty affiliations with other colleges as well.

3. In the course of my practice, I provide direct patient consultations and comprehensive medication-related consults, conduct clinical trials with new and existing therapeutic agents and provide consulting and continuing education services for managed care plans, hospitals, pharmacies, and pharmaceutical companies. I routinely provide forensic consultations and testimony for law enforcement, medical examiners offices, laboratories, and courts including State, Federal, and Military agencies, and courts. Throughout my career, I have been a member of and served in leadership roles in numerous professional associations, including at a local, state, and national level. I have also served as a Medication Safety Expert with the US Department of Health's (DHHS) Center for Medicare and Medicaid Services (CMS), Center for Medicare and Medicaid Innovation (CMMI), and Health Resources and Services Administration (HRSA).

4. As part of my professional scope of practice, research initiatives, and professional services, I evaluate the clinical and forensic applications of pharmaceutical substances based upon their pharmacokinetic profiles (i.e., absorption, distribution, metabolism, and eliminations) and pharmacodynamics profiles (i.e., pharmacologic effects and mechanisms of action) in order to achieve targeted outcomes. The pharmaceutical substances utilized with the Nevada's lethal injection manual have

an abundance of medical and scientific literature that serve as a basis for understanding their respective pharmacologic and toxicologic properties. This collective information and years of practical experience provides a rationale and basis for their selection and utility within the execution process.

Plaintiff's Claims:

5. “The two potential initial drugs, fentanyl and alfentanil, do not reliably block awareness, are largely untested in executions and litigation, and can interfere with reliable assessments of awareness.” Page 12:21-23

Fentanyl is a potent opioid analgesic used in clinical practice to provide pain relief, prevent, or relieve tachypnea and postoperative emergence delirium, provide preoperative anxiolysis and sedation, or as a supplement to regional or general anesthesia. Compared to other opiates, fentanyl exhibits less hypnotic effect, but this should not be interpreted as meaning that the drug is unable to induce a state of anesthesia or unconsciousness such that a person would remain aware and sensate to pain. The FDA-approved package insert for fentanyl citrate (intravenous formulation) lists the labeled indication for use as an anesthetic agent with oxygen in certain patients. This use as an anesthetic, for induction and maintenance, is primarily in patients undergoing cardiopulmonary procedures due to the cardiovascular stability associated with fentanyl compared to other anesthetic agents. The manufacturer’s recommended doses of fentanyl for use as an adjunct to anesthesia is 20-50 mcg/kg and for general anesthesia is 50-100 mcg/kg. Dosing for producing analgesia include 12.5-100 mcg (transdermal) and 50-100 mcg (IM or IV) prior to surgical procedures. Serious adverse events, including fatalities have occurred, even within these standard dosing ranges, if you initiated therapy at the higher end of dosing schedules. In clinical practice, patients initiating fentanyl analgesic therapy should always start with the lowest possible dose and titrate upward based on degree of pain relief and patient safety.

Plaintiff’s claim that fentanyl cannot “reliably block awareness” is both medically and scientifically unsupportable. Furthermore, the purpose of fentanyl as provided in the Nevada lethal injection manual is

not to act as the sole agent to produce “unawareness,” thus the Plaintiff’s concern over the well-established ability of fentanyl to induce and maintain loss of awareness is irrelevant.

Alfentanil is a potent opioid analgesic opioid anesthetic and analgesic derivative of fentanyl. It produces an early peak analgesic effect and is effective as an anesthetic during surgery, for supplementation of analgesia during surgical procedures, and as an analgesic for critically ill patients. It can be used in clinical practice to provide pain relief, prevent, or relieve tachypnea and postoperative emergence delirium, provide preoperative anxiolysis and sedation, or as a supplement to regional or general anesthesia. Compared to other opiates, alfentanil interacts with the opioid mu-receptor. These mu-binding sites are discretely distributed in the human brain, spinal cord, and other tissues. In clinical settings, alfentanil exerts its principal pharmacologic effects on the central nervous system.

The FDA approved indications include, 1) as an analgesic adjunct given in incremental doses in the maintenance of anesthesia with barbiturate/nitrous oxide/oxygen, 2) as an analgesic administered by continuous infusion with nitrous oxide/oxygen in the maintenance of general anesthesia, and 3) as a primary anesthetic agent for the induction of anesthesia in patients undergoing general surgery in which endotracheal intubation and mechanical ventilation are required. Alfentanil is often used as the analgesic component for monitored anesthesia care (MAC).

The primary pharmacologic effects (i.e., analgesia) of alfentanil and especially at high doses will render an individual insensate to pain. The manufacturer’s recommended doses of alfentanil for the induction of analgesia is 20-50 mcg/kg and for the induction of anesthesia is 130-245 mcg/kg. It has a rapid onset of action. The duration of action (anesthesia for surgical procedures) lasts up to 30 minutes following doses of 8 mcg and higher. Alfentanil provides analgesic protection, for up to 45 minutes, against hemodynamic responses to surgical stress with recovery times generally comparable to those seen with equipotent fentanyl dosages.

Plaintiff's claim that alfentanil cannot "reliably block awareness" is both medically and scientifically unsupportable.

Furthermore, the purpose of alfentanil as provided in the Nevada lethal injection manual is not to act as the sole agent which produces "unawareness," thus the Plaintiff's concern over the well-established ability of alfentanil to induce and maintain loss of awareness is irrelevant.

6. Fentanyl and alfentanil are "very likely to cause chest wall rigidity, which prevents breathing and movement" and "Floyd would experience the chest wall rigidity and the anguish of the sensation of being unable to breath." Page 13:1-2, 3-5

Opioid-induced chest wall rigidity is described as increased muscle tone of the thoracic and abdominal muscles after administration of opioids. Chest wall rigidity is an uncommon complication that is theorized to be associated with supratherapeutic doses of opioids and has been observed primarily with isolated cases of fentanyl use in neonates and infants. Few cases reports have described with low doses of fentanyl. While a warning regarding this uncommon side effect of general muscle rigidity is mentioned in the package inserts for fentanyl and alfentanil, the available supporting literature on this phenomenon is limited to case reports where insufficient ventilation was recognized in patients through a noticeable trend in desaturation with both spontaneous ventilation and in patients who were mechanically ventilated. On rare occasions did the muscle rigidity pose a problem with patient management. In most cases similar symptoms were reversed with the administration of a muscle relaxant and naloxone. Additionally, the package insert suggests coadministration of a neuromuscular blocking agent to mitigate muscle rigidity. The current medical literature, including literature reviews and case reports, provide limited detail on the proposed mechanism, pathophysiology, occurrence rate, and any impact on treatment outcomes are very inconsistent. The theoretical concern is that there may be a rare potential for a fatal outcome due to an inability to ventilate spontaneously or respond to mechanical ventilation. However, this would not be a relevant concern during

a lethal injection procedure as death is a targeted outcome. This criticism, even if this did occur, it would become a benefit that could hasten and accelerate the procedure.

Additionally, it has not been hypothesized anywhere in the medical literature, nor does it make any pharmacologic sense, that a person would be sensate to or aware of the feelings of chest wall rigidity. Onset of rigidity in clinical settings is hypothesized to be related to the dose, but this is an unconfirmed theory and there is no evidence to support any assertion that this (a) would, with any certainty, occur during the lethal injection procedure, or (b) if it were to occur in the rarest of circumstances, that it would occur prior to the rapid onset of analgesic and anesthetic effects. The higher the dose of opioid, the greater the levels of analgesia and anesthesia, which abate an individual's awareness and level of consciousness. There is no evidence to support the Plaintiff's speculative claim that Floyd will "very likely" experience the rare side effect of chest wall rigidity, nor is there any evidence to support the claim that he would be aware of any discomfort. It appears that the Plaintiff is attempting to, and without merit, infer that the any sensation associated with chest wall rigidity would result in cognitive emergence from the profound central nervous system depression that would have already been induced by the opiates. This is a fantastical and unsupportable premise.

7. "Fentanyl and alfentanil can interfere with consciousness checks by causing the execution team to conflate severe dissociation with unawareness." Page 13:7-9

Plaintiff appears to be confused as to the definitions of and distinct differences between a dissociative state, a psychiatric state characterized by a feeling of detachment from reality in which a person remains awake and reactive, versus unconsciousness which is characterized by a loss of awareness and arousability. There is no evidence to support the claim that Plaintiff is very likely to experience a dissociative state as a direct result of fentanyl administration as this is not a common side effect of opioids, and it is illogical to assume that anyone, regardless of level of medical training, would conflate or be unable to distinguish between states of dissociation versus unconsciousness.

Plaintiff may have intended to assert that the execution team would conflate dissociative *anesthesia* with unconsciousness. Dissociative anesthesia is a form of anesthesia characterized by catalepsy (loss of voluntary motion), catatonia (state of unresponsiveness), analgesia, and amnesia. Dissociative anesthesia does not always imply a loss of consciousness depending on the level of sedation. Fentanyl is not associated with or known to produce this type of anesthesia or clinical outcome, thus any concerns over potential confusion on behalf of the execution team are not an issue.

8. “When Floyd proffered fentanyl in his complaint, he intended it to be a low therapeutic dose for pain relief, not a bolus of fentanyl.” Page 13:20

The substantially higher doses of both fentanyl and alfentanil, as outlined within the Nevada execution manual, would produce far greater levels of both analgesia and anesthesia than what Floyd proposed in his complaint. At these higher doses, he would not be aware of or sensate to pain or discomfort and with no rationale that he could even sense a rare occurrence of chest wall rigidity, this complaint is defective and without merit.

9. Ketamine is disfavored for use as an anesthetic because of the severe side effects it carries: psychosis, laryngospasm, excessive secretions from the mouth causing laryngospasms, and vomiting. Page 13:15 – 14:2

Use of ketamine as an anesthetic agent is still common and is in fact a preferred agent for certain procedures (e.g., unstable cardiovascular patients, hypovolemia, reactive airway disease, etc.). Its use in routine procures is limited, however, this is due primarily to the high propensity of producing emergence symptoms and stimulation of the cardiovascular system. The concerns over the undesirable psychiatric reactions to ketamine are related to the emergence of these symptoms upon *awakening* from anesthesia (i.e., emergence symptoms), which would not be a concern in the case of carrying out a lethal injection manual. Additionally, while hemodynamic stability is a factor in clinical practice settings and long procedures, this should not be considered a limiting factor in the lethal injection process.

Laryngospasm associated with administration of ketamine is an uncommon idiosyncratic adverse event characterized by involuntary muscle movement and spasm of the vocal cords within the larynx. This phenomenon is not strictly associated with ketamine use and occurs within the general population in response to various triggers, including allergies, irritants, exercise, anxiety, and most commonly gastroesophageal reflux disorder (GERD). Laryngospasm is sudden in onset and resolves quickly, and while individuals may report emotional responses the experience is not associated with causing pain. Furthermore, there is no evidence to support any assertion that the inmate would be sensate to or aware of a laryngospasm if it were to occur.

10. Ketamine is not capable of producing a “flat line EEG” which is the “hallmark” of other anesthetics, and a “flat line EEG” indicates unawareness. Page 14:3-5

The FDA-approved indications for ketamine are solely related to use as an anesthetic or as a supplement for anesthesia. The labeled indications include (a) as the sole anesthetic agent for diagnostic and surgical procedures that do not require skeletal muscle relaxation, (b) for the induction of anesthesia prior to the administration of other general anesthetic agents, and (c) as a supplement to other anesthetic agents.

Ketamine is a rapid-acting general anesthetic producing a dissociative anesthetic state characterized by profound analgesia (via multiple pathways), normal pharyngeal-laryngeal reflexes, normal or slightly enhanced skeletal muscle tone, cardiovascular and respiratory stimulation, and occasionally a transient and minimal respiratory depression. As described above, dissociative anesthesia is a form of anesthesia characterized by catalepsy (loss of voluntary motion), catatonia (state of unresponsiveness), analgesia, and amnesia. Dissociative anesthesia does not always imply a loss of consciousness depending on the level of sedation. However, ketamine produces dose-related unconsciousness and analgesia through its action at NMDA (N-methyl-D-aspartate) receptors, opioid receptors, and monoaminergic receptors. Of greatest importance is the action of ketamine’s inhibition of NMDA-mediated glutamergic input to the GABA-ergic system which reduces excitatory activity in the limbic system and ultimately results in

unconsciousness. The reason that the state of anesthesia produced by ketamine is referred to as dissociative anesthesia is because these patients appear to be in a cataleptic state versus appearing to be in a normal state of sleep as with other anesthetics.

Plaintiff's claim that a "flat line EEG" indicates unawareness only serves to demonstrate their fundamental lack of understanding of both the pharmacology of ketamine and the interpretation of EEG. It is well-established that the mechanism of action and pharmacodynamics of ketamine are unique and vary greatly compared to other agents used for anesthesia, and the ability of ketamine to produce unconsciousness falls outside of the mechanistic framework for all other anesthetic agents. Ketamine tends to increase the power of high-frequency EEG activity, whereas most anesthetics depress this bandwidth. Plaintiff's elementary attempt to define "unawareness" by "flat line EEG" is without merit as it is a known fact within the medical and pharmacologic fields that ketamine is indicated and used routinely for the induction of unconsciousness and will not produce an EEG pattern consistent with those of other general anesthetics. The dose of ketamine utilized in the lethal injection manual is sufficient to produce a state of general anesthesia.

11. Ketamine in large quantities burns the veins and lungs, causing extreme pain and pulmonary edema because it is a strong acid. Page 14:5-7

Ketamine has a low molecular weight, a pKa near the physiologic pH, and high lipid solubility contributing to its rapid onset of action. Injection site pain or reactions are not associated with the drug itself, and there is no evidence to support the theory that administration of ketamine would "burn the veins and lungs" or cause any degree of pain.

12. Ketamine will interfere with consciousness checks. Page 14:7-9

Plaintiff has failed to provide an explanation or any evidence as to how this interference may occur or demonstrate that it is "very likely" to occur. Ketamine is being used for and will produce a state of unconsciousness as the dose provided in the lethal injection manual.

13. Cisatracurium will mask any problems from the administration of the other drugs, while providing no medical benefit. Page 14:12-14

Cisatracurium, or any other neuromuscular blocking agent, when administered with fentanyl will aid in the mitigation of muscle rigidity if it were to occur.

Additionally, the clinical effects of the first and second drugs, consciousness checks performed after administration of the first and second drugs, and the duration of effect of fentanyl/alfentanil and ketamine, are sufficient such that the inmate will not be aware of or sensate to the clinical effects of the subsequent drugs administered. There is no evidence to support the implication that the first steps of the lethal injection manual will fail or result in problems.

14. “It is widely accepted that potassium chloride is ‘an extraordinarily painful chemical’ because it “causes burning and intense pain as it circulates throughout the body”; “Potassium acetate is no better”; “The protocol creates a substantial risk that the potassium chloride or potassium acetate will be administered while Floyd is not properly anesthetized, causing Floyd to suffer excruciating pain.” Page 15:13 – 16:5

Plaintiff has no basis for the presumption that the drugs administered in steps 1-3 will fail to produce the well-known and expected clinical effects and induce and maintain a state of unconsciousness. There is no inherent risk of these agents failing to achieve anesthesia, and thus no inherent risk that the inmate will experience any pain or other IV injection site reactions related to the administration of the final drug.

15. (Proposed Alternative) Execution solely using a barbiturate such as pentobarbital or sodium pentothal (thiopental) would significantly reduce the substantial risk of pain inherent in Nevada’s current protocol because a barbiturate reliably induces and maintains a coma-like state that renders a person insensate to pain and necessarily precedes death. Page 17:11-15

The Plaintiff's claim is without medical and scientific support. There is no documentation or valid premise to state that Floyd would have a "substantial" risk of pain or a method to opine their comparative level of pain from either a single barbiturate (such as pentobarbital) or the 4-drug or 3-drug regimens as outlined within the Nevada lethal injection manual. In my professional opinion, there is no rationale to believe that he would experience pain from any of the above listed regimens.

In addition, there is no mandate or expectation that an inmate be either insensate to pain, "coma-like," or be in general anesthesia as described in their complaint. Even the American Society of Anesthesiologists definitions of Continuum of Depths of Sedation: Definition of General Anesthesia and Levels of Sedation/Analgesia is the term "coma-like" ever defined or referenced to support such a speculation.

In addition, their complaint proposes the alternative use of barbiturates, such as sodium pentobarbital (Nembutal®) and sodium thiopental (Pentothal®). This complaint is disingenuous because neither of these agents are available for acquisition, purchase, or use by states Departments of Corrections due to the collusion and restrictions between pharmaceutical manufacturers and drug wholesalers that openly preclude such access under commercial duress and penalty.


Conclusion:

12. Plaintiff's unsupportable claims and concerns regarding the use of fentanyl or alfentanil, ketamine, cisatracurium, and potassium chloride or potassium acetate openly contradict the well-established pharmacologic properties and the clinical and toxicologic effects of these agents. Plaintiff has also grossly mischaracterized and exaggerated the risk of occurrence and severity of rare adverse effects that have been observed with fentanyl, alfentanil, and ketamine. It is my opinion that the Nevada Department of Corrections Execution Manual, via the pharmaceutical substances employed within, either 4-drug or 3-drug regimens, will produce and maintain a sufficient level of analgesia and anesthesia such that the inmate will be rendered unconscious and insensate to pain for the duration of the lethal injection procedure. It is further my opinion that the drugs utilized in the lethal injection manual do not carry an

inherent risk of causing increased pain or other complications that would interfere with the lethal injection process.

13. I declare under penalty of perjury pursuant to 28 U.S.C. section 1746 that the foregoing is true and correct.

Further affiant sayeth naught.


Dr. Daniel E. Buffington

SWORN TO AND SUBSCRIBED before me this 24th day of June 2021.


☒ Personally known

☒ Identification produced ID Type - Florida Driver's License


Name

NOTARY PUBLIC, STATE OF FLORIDA

My Commission Expires:



20210624.2

ATTACHMENT 1 – CV

CURRICULUM VITAE

DANIEL E. BUFFINGTON, PharmD, MBA

Clinical Pharmacology Services, Inc.
6285 E. Fowler Ave
Tampa, FL 33617

813-983-1500 Work
813-983-1501 Fax
813-679-0792 Cell

PERSONAL:

Place of Birth	Clearwater, FL
Citizenship	United States

EDUCATION:

Postgraduate	Emory University Hospital	
	Pharmacy Practice Residency	07/1987 – 06/1988
	Clinical Pharmacology Fellowship Atlanta, GA	07/1988 – 06/1989
Graduate	Mercer University, School of Pharmacy	
	Doctor of Pharmacy	08/1983 - 06/1987
	Atlanta, GA	
	Mercer University, College of Business & Economics	
	Master of Business Administration	06/1987 – 05/1995
	Atlanta, GA	
Undergraduate	University of South Florida	
	Biology	08/1980 – 08/1983
	Tampa, FL	

SPECIALTY TRAINING:

National Association of Drug Diversion Investigators (NADDI)
Southern Regional Training
St. Pete Beach, FL
May 7-8, 2015

Transportation & Management of Hazardous Materials
Morton Plant Mease, Certificate Program
Tampa, FL
September 8, 2001

Nephrology Preceptorship

University of Pittsburgh, School of Pharmacy
Pittsburgh, PA
October 25, 1995

EMPLOYMENT:

03/2014 – Present	United States Center for Medicare and Medicaid Services (CMS) Washington, DC & Baltimore, MD Center for Medicare and Medicaid Innovation (CMMI) ORISE Fellow – Medication Safety Expert 03/2014 – 10/2016 Center for Clinical Standards and Quality (CCSQ) Technical Expert - Medication Management and Safety 11/2016 - Present
01/2007 – Present	American Institute of Pharmaceutical Sciences, Inc. President & CEO Tampa, FL
05/1991 – Present	University of South Florida College of Medicine Department of Internal Medicine Division of Clinical Pharmacology Clinical Associate Professor of Medicine Tampa, FL 05/1991 - Present College of Pharmacy Department of Pharmacotherapeutics and Clinical Research Clinical Associate Professor of Pharmacy Tampa, FL 2011 - Present College of Nursing Clinical Pharmacology for Advanced Registered Nurse Practitioners 1998 - 2002
01/1990 - Present	Clinical Pharmacology Services, Inc. President & CEO Tampa, FL

PRIOR EMPLOYMENT:

10/2013 –07/2015	North Shore Long Island Jewish Health System CareConnect® and LiveWell® Director of Pharmacy Long Island, NY
------------------	--

06/1989 - 06/1991	H. Lee Moffitt Cancer Center Gynecology/Oncology, Infectious Diseases, Clinical Research Clinical Pharmacist Tampa, FL
03/1989 - 09/1990	Professional Designs, Inc. Presentation Graphics & Design Consulting President Atlanta, GA
01/1985 - 06/1989	Beta Technology Medical Computer Systems and Presentation Consulting President Atlanta, GA

LICENSES:

Florida (Pharmacy)	PS 0024260
Georgia (Pharmacy)	150301

FACULTY AFFILIATIONS:

Marshall University	School of Pharmacy Adjunct Faculty Huntington, WV 2018 – Present
Belmont University	College of Pharmacy Clinical Preceptor Nashville, TN 2018 – Present
University of Connecticut	College of Pharmacy Clinical Preceptor Storrs, CT 2012 – Present Guest Professorship 02/2012 – 04/2012
Lake Erie College of Osteopathic Medicine	College of Pharmacy Clinical Preceptor Bradenton, FL 2010 – Present
Creighton University	College of Pharmacy Clinical Preceptor Omaha, NE 2007 – Present
Shenandoah University	College of Pharmacy Clinical Preceptor Winchester, VA 2004 – Present

Idaho State University	College of Pharmacy Affiliate Faculty Member Potatello, ID 2004 – Present
Palm Beach Atlantic University	Lloyd L Gregory School of Pharmacy Clinical Instructor of Pharmacy Practice West Palm Beach, FL 2003 – Present
Mercer University	Southern School of Pharmacy Adjunct Faculty, Department of Pharmacy 2000 – Present
Florida A&M University	College of Pharmacy Clinical Preceptor Tampa, FL 1999 – Present
Nova Southeastern University	College of Pharmacy Department of Pharmacy Practice Clinical Assistant Professor of Pharmacy North Miami Beach, Florida 1996 – Present
University of South Florida	College of Medicine College of Pharmacy College of Nursing (ARNPs) 1991 – Present
University of Florida	College of Pharmacy Department of Pharmacy Practice Assistant Clinical Professor & Clinical Preceptor 1990 – Present

PROFESSIONAL & COMMUNITY ORGANIZATIONS:**NATIONAL**

Healthcare Information and Management Systems Society (HIMSS) 2018 – Present

- Member North American Chapter

National Academies of Practice 2016 – Present

- Practitioner Fellow

American Pharmaceutical Association (APHA), 1985 – Present

- Government Affairs Committee 2013 – Present
- Board of Trustees Executive Committee,
 - First Term 2011 – 2014
 - Second Term 2016-2019
- Finance Committee, 2016 - 2019
- APHA Delegate, 2011 – Present
- Strategic Directions Committee, 2011 - Present
- STAT Task Force - Reimbursement for Pharmacy Services, 1995, 1996
- Academy of Pharmaceutical Care Specialists, 1996 – Present
- Student APA, Vice-President, 1983 -1985

Board of Pharmacy Specialties, 2009 - 2012

- Oncology Specialty – Exam Question Development
- Pharmacotherapy Specialty – Exam Question Development
- Ambulatory Care Specialty Counsel, 2009 – 2012

American Medical Association (AMA), 2004 - Present

- CPT/RUC Emerging Issues Workgroup 2015 - 2019
- Therapeutic Drug Monitoring Workgroup, 2013 – 2016
- Drug Infusion Workgroup, 2005 – 2009
- Current Procedural Terminology, Editorial Panel, CPT Advisor, 2004 - Present
- Healthcare Professional Advisory Committee, Pharmacy, 2004 - Present

American College of Clinical Pharmacology (ACCP), 1991 - Present

- Program Planning Committee, 1992 - 1994

American College of Clinical Pharmacy (ACCP), 1988 - Present

- Clinical Affairs Committee, 1991 -1992
- Reimbursement Task Force, 1993 -1994
- Public & Professional Relations Committee, 1994 -1995

American Society of Consultant Pharmacists, 1988 – Present

American Society of Health-System Pharmacists (ASHP), 1985 – Present

- Specialty Practice Group (SPG):
- Vice-Chair, 1996 – 1997
- Public Policy and Government Relations Committee, 1995 – 1996
- Section for Clinical Specialist, 1995 - Present
- Vice-Chair, 1993 -1994
- Task Force on Unlabeled Uses of Medications, 1993 - 1994
- House of Delegates, 1993 – present
- Clinical Pharmacokinetics, 1990 -1995

International Society for Pharmacoeconomics and Outcomes Research, 2000 - 2003

American Society of Microbiology (ASM), 1992 – 1997

STATE

American Cancer Society, Hillsborough County, 1991 -1993

- Board of Directors, 1991 - 1993

American College of Clinical Pharmacology, Tampa Chapter, 1989 – Present

- Tampa Chapter, Program Committee, 1991 - 1993

Association for Clinical Research Professionals – SunCoast Chapter, 1999 - 2000

- SunCoast Chapter, President-elect, 1999
- SunCoast Chapter, President, 2000

Florida Society of Health-System Pharmacists, 1989 – Present

- Experiential Education Innovation Forum - 2012
- House of Delegates, 2011 - Present
- Legal and Regulatory Affairs Council Chairman, 1992, 1993 member, 2002-2005
- President, 2000 - 2001
- President Elect, 1999
- Educational Affairs Council, Council Chairman, 1998
- House of Representative, 1993 - present
- Reimbursement Task Force, 1993 - 1995
- Board of Directors 1993 -1995
- Communications Council/Board Liaison, 1993 – 1994

- Board of Directors, 1992 - Present
- Clinical Council/Chair, 1992 -1993
- Editor, FSHP/Digest, 1990 -1993
- Clinical Council/member, 1990 -1992

Southwest Florida Society of Hospital Pharmacists, 1989 – 2003

- President, 1992 - 1993
- President-Elect, 1991 - 1992
- Nominations Committee 1990 - 1991

Florida Pharmacy Association, 1991 – Present

- Government Affairs Committee, 2012 - Present
- Professional Affairs Council, 2000 – 2002; 2012-2014
- Public Affairs Committee, 1993
- Public Relations Committee, 1992 -1993

Hillsborough County Pharmacy Association, 1991 - 2010

- Board of Directors, 1992 -1993

Atlanta Academy of Institutional Pharmacist, 1987 -1990

University of South Florida, 1993 - 1996

- USF Institutional Review Board, Human Research, 1994 – 1996
- USF Community Music Division, Board of Directors, 1994 -1996
- Health and Safety Committee, 1993 - 1996

Mercer University School of Pharmacy, 1984 - 1987

- National Deans List, 1986 -1987
- Mercer Dean's List - 1986, 1987
- Class of 1987, Vice-President, 1985 -1987
- Class of 1987, Secretary, 1984 -1985
- Georgia Pharmaceutical Association: Board of Directors/Student Rep, 1984

Florida Pharmacy Foundation, 2012 - 2013

- Board of Trustee, 2012 - 2013

Florida Community Pharmacy Network and Political Action Committee 2009 - Present

COMMUNITY

LifePath Hospice and Palliative Care, 1999 - Present

- Executive Committee, 2005 - Present
- Bioethics Committee, Chairman, 2001 – 2003
- Board of Directors, Tampa, FL, 1999 – Present

METRO BAND, Christian Music Ministry, 1994 – Present

Idlewild Baptist Church, Orchestra, 1989 – Present

Great American Teach-In, 2001 – 2012

- Young Middle Magnet School
- Lewis Elementary School

Hillsborough Regional Science Fair Judge, 2003 and 2001

SideFX: Medical Band (Charity Functions), 1993 – 2005

Judeo Christian Health Clinic Volunteer, 1991-1995

Paint Your Heart Out Tampa, Hillsborough County Medical Association, 1989-1991

Community Relations Board, Ex-Officio Member, City of Clearwater, 1979

FRATERNITY - PROFESSIONAL

Kappa Psi Pharmaceutical Society, 1984

Phi Lambda Sigma - Leadership / Honor Society (Mercer University), 1985

- Vice-President, 1986 -1987
- National Convention Representative, 1986

FRATERNITY – SOCIAL

Sigma Alpha Epsilon Fraternity, 1981

PROFESSIONAL APPOINTMENTS AND ENGAGEMENTS:

10-04-2009	National Dean's Advisory Council University of Florida, College of Pharmacy Gainesville, FL
01-13-2009	Medication Measures Special Study Technical Expert Panel Quality Partners of Rhode Island
06-01-2006	Pharmacy Quality Alliance (PQA) Center for Medicare and Medicaid Services (CMS) Baltimore, MD
12-12-2005	Technical Advisory Panel: Center for Medicare & Medicaid (CMS), Medicare Prescription Drug, Improvement and Modernization Act of 2003 Baltimore, MD (BearingPoint)
04-03-2005	Board of Pharmaceutical Specialties (BPS) Focus Group Pharmacy Certification Programs, Orlando FL
12-18-2003	Health Care Professionals Advisory Committee (HCPAC) American Medical Association, Current Procedural Terminology (CPT) Editorial Panel, 2003 – Present
11-15-2002	Pharmacists Services Technical Advisory Coalition (PSTAC) Representing the American Society of Health-Systems Pharmacists 2002 – Present
11-01-2002	Mercer Southern School of Pharmacy Campaign Committee Associate Chair
10-02-2002	Dean's Advisory Board of Visitors Mercer University, Southern School of Pharmacy, Atlanta, GA
09-23-2000	Dean's National Advisory Board University of Florida, College of Pharmacy, Gainesville, FL
07-16-1999	National Faculty: Managing Respiratory Tract Infections in the New Millennium Thomas Beam, Jr. Memorial Institute, Bayer, Denver, CO

EDITORIAL REVIEW BOARD:

American Journal of Health-System Pharmacy Supplement, Guest Editor, 2007

American Pharmacists Association, Reviewer, 2007

Cancer Control - Journal of the Moffitt Cancer Center

Florida Digest, Co-Editor, 1991, 1992, 1993

Florida Journal of Hospital Pharmacy

Clinical Pharmacy

American Journal of Hospital Pharmacy

Hospital Pharmacy

HONORS / AWARDS / SCHOLARSHIPS:

Preceptor Award

Palm Beach Atlantic University Gregory School of Pharmacy 2018

Distinguished Service Award, 2016

Florida Society of Health-System Pharmacists

Florida Pharmacist of the Year - James H Beal Award, 2016

Florida Pharmacy Association

Outstanding Achievement in the Field of Pharmaceutical Relations in Florida

R Q Richards Award, 2015

Pharmaceutical Public Relations

Outstanding Pharmacy Service Award, 2013

University of Florida, College of Pharmacy

Appreciation for Service, Mock Trial, 2011 - 2018

University of South Florida, College of Pharmacy

APhA Practice Excellence - Daniel B. Smith Award, 2010

American Pharmacists Association

Education Awareness Certificate, 2009

University of South Florida

APhA Pinnacle Award, 2008

American Pharmacists Association Foundation

Award of Excellence, 2008

American Society of Health-System Pharmacists

The Inaugural Distinguished Alumni Award, 2009

Mercer University, College of Pharmacy & Health Sciences

NetSmartz® Sponsorship Award, 2007

Hillsborough County

Dr. G. Van Greene Distinguished Lecturer, 2005

Mercer University College of Pharmacy

Distinguished Achievement Award in Clinical Pharmacotherapeutic Practice, 2005

Academy of Pharmacy Practice and Management
American Pharmacists Association

Florida Pharmacist of the Year, 2002

Florida Society of Health-System Pharmacists

Florida Pharmacist Fore Runner Award, 1994

Florida Society of Hospital Pharmacists

President's Award, 1993

Florida Society of Hospital Pharmacists

Distinguished Service Award, 1991 -1993

Florida Pharmacy Association

Outstanding Service Award, 1993

Florida Society of Hospital Pharmacists

Bristol Laboratories Award, 1987

Mercer University, School of Pharmacy

Collegiate Student Government Award, 1987

Mercer University

Outstanding Young Men of America Award, 1987

Mercer University

United States Achievement Academy Award, 1987

Mercer University

Georgia Pharmaceutical Association, 1986

Scholarship

Churches Home Foundation, 1986

Scholarship

Clearwater Community Service Award, 1980

City of Clearwater, FL

PHILANTHROPY:

International Health Service Collaborative (2017)

Children's Hospital (2015 - 2016)

Pediatric Cancer (2014)

Ruth Eckerd Hall (2013 – 2018)

AIM Convention Health Fair 2012

Autism Speaks (2010 - 2015)

Make A Wish Foundation (2010 - 2012)

Denver & the Mile-High Orchestra 2010

Global Missions Project – Russia

Temple Terrace Rotary Club – Linwood Park 2010

Opening ceremony

Idlewild Baptist Church

Cuba Missions Trip (2009 – Present)

University of Florida Foundation (2009 - 2014)

Steve McCauley Memorial Golf Tournament 2009

Proceeds benefit the Steve McCauley Memorial Scholarship Fund

Children's Dream Fund (2009)
Temple Terrace Rotary Foundation (2008)
University of South Florida Library Fund (2007 – 2014)
Ohio State University Pharmacy Society (2007 - 2010)
Hillsborough County – NetSmartz® Launch 2007
 Internet Safety for Kids
Cross International (2007)
Global Missions (2006 - 2011)
Stamford University (2006 - 2008)
Breast Cancer Donation (2006)
Cystic Fibrosis Foundation (2006)
University of South Florida Foundation (2005 – Present)
American College of Clinical Pharmacy (2005 - Present)
American Pharmacists Association (2005 – Present)
American Cancer Society (2005 - 2010)
Mercer University (2002 - 2016)
Muscular Dystrophy Association (2002 – 2012)
American Society of Consultant Pharmacists Foundation (2001 – Present)
Kayla's Hope for Kids Golf Tournament 2001 - 2014
 Proceeds benefit The Children's Hospital of Philadelphia, Division of Neuro-Oncology
Florida Family Association (2001 - 2006)
LifePath Hospice and Palliative Care 1999 - 2016
 Board of Directors and committee work

MUSIC PERFORMANCES:

06-22-2005	Southern Baptist Convention, Nashville, TN Celebration Orchestra, Idlewild Baptist Church
03-22-2004	Cuba National Orchestra: Global Missions Project, Havana, Cuba National Theatre Performance (03-25-2004) Concert in the Park, Plaza De Armas (03-26-2004)
2003 - Present	Idlewild Baptist Church, Tampa, FL, Celebration Choir and Orchestra
01-29-1999	Academy of Gospel Music Arts Orlando Region, Metro Band
1993 - 2005	SideFX: Medical Band

POSTER PRESENTATIONS:

Evaluation of the Utility of Sinus Endoscopy versus Sinus Aspiration for Microbiologic Documentation of Acute Maxillary Sinusitis-Zagam Endoscopy Study Group
 International Conference on Antimicrobial Agents and Chemotherapy 35th (ICAAC)
 San Francisco, CA, 09-15-1995

Development of Reimbursement Mechanisms for Pharmacist Services
 American Pharmacy Association 1995 Annual Meeting
 Orlando, FL, 03-19-1995

Creation of a Software Program to Assess Patient Risk Factors for the Development of Candidemia

American Society of Hospital Pharmacists, Midyear Clinical Meeting
Miami Beach, FL 12-06-1994

Task Force on Reimbursement for Cognitive Services Report

ACCP Annual Meeting
08-15-1993

Clinical Pharmacokinetics: Software Review

American Society of Hospital Pharmacists, Clinical Midyear Meeting
Dallas, TX 12-07-1988

COURSE LECTURES:

University of South Florida, College of Nursing

Tampa, FL

**Clinical Pharmacology for Advanced Nurse Practitioners
(USF, NGR 6199)**

Registered Nurse Practitioners - Graduate Program
Course Director
1998 – 2002

University of South Florida, College of Pharmacy

Tampa, FL

Medical Informatics and Technology

Interoperability and Health Information Exchanges
2018

Pharmacy Management

Managing People – Human Resource Management
2017

Pharmacy's Role in the US Healthcare System

2017

The Future of Pharmacy

2016

Healthcare Administration and Economics

2016

Drugs of Abuse & Forensic Pharmacology

2013 – Present

Pharmacy Practice Orientation

2014 - 2016

Pharmacy Leadership

Professional Pharmacy Advocacy
2014

USF AMCP Student Group Lecture

2016

University of South Florida, College of Public Health

Tampa, FL

Pharmacoepidemiology (6934) – “Pharmacoeconomics”

Lecturer

[insert Years]

University of Florida College of Pharmacy

Gainesville, FL

Clinical Pharmacokinetics (PHA 4123, PHA 5121)

Aminoglycosides & Vancomycin Pharmacokinetics: Clinical Applications

BS & Doctor of Pharmacy Programs

Pharmacy Management (PHA 4210)

“Reimbursement for Pharmaceutical Care Services”

BS & Doctor of Pharmacy Programs

Clinical Pharmacy & Therapeutics

Non-Traditional Doctor of Pharmacy Program

Topics:

- Pharmacokinetics
- Gynecologic Malignancies
- Infectious Diseases (Sinusitis, Infectious Diarrhea)
- Allergic Rhinitis

University of Connecticut - School of Pharmacy Department of Pharmacy Practice

Hartford, CT

Creating, financially sustaining, and providing MTM Services

2012

MTM and Pharmacists' Practice Models

2012

Lake Erie College of Medicine

Erie, PA

Toxicology Lecture

2015 - 2016

Forensic Pharmacology

2014

University of Washington

Seattle, WA

2013

Preceptor Development Conference

Ft Myers, FL

Encouraging Critical Thinking Skills in Students and Residents

2013

Nova Southeastern University

Ft Lauderdale, FL

Strategic Positioning of MTM Services and Reimbursement in HealthCare Reform

2012

Philadelphia College of Medicine

Philadelphia, PA

[title of lecture]

2011

University of Pittsburgh, School of Pharmacy

Pittsburgh, PA

Nicholas C. Tucci Lecture

2009

West Virginia University, School of Pharmacy

Morgantown, WV

Annual Bergy Lecture

2011

University of Maryland

Baltimore, MD

Future of Medication Therapy Management: Winning or Loosing

2008

Mercer University Southern School of Pharmacy Inaugural Distinguished Lecture

Atlanta, GA

Medicare Modernization Act

Focus on Improving Care

2005

Bernard J. Dunn School of Pharmacy at Shenandoah University

Washington, DC

Hooding Ceremony – Guest Speaker

2018

University of South Florida

Tampa, FL

Interoperability and Health Information Exchange

2018

PUBLICATIONS:

Opiate Disposal/Pain Research/Bufington D (Purdue Pharma)
Understanding factors that contribute to the disposal of unused opioid medication
 Sep 2018

Brill J, Ashmore J, Buffington D, Brengman M, Streett S
White Paper AGA: An Episode-of-Care Framework for the Management of Obesity:
 Moving Towards High Value, High Quality Care
 Clinical Gastroenterology and Hepatology the Official Clinical Practice Journal,
 Feb 2017

Whalen K, Hardin H, Buffington D
Medication Therapy Management: A Pharmacotherapy and Medication System
 Primer, McGraw-Hill, 2017

Green D, Rubenstein A, Buffington D, Martin D
Leveraging FDA and CMS collaboration to enhance quality improvement in safe
 medication use
 Research in Social and Administrative Pharmacy, Jul 2016

Isetts B, Buffington D, Carter B, Smith M, Polgreen L, James P
Evaluation of Pharmacists' Work in a Physician-Pharmacist Collaborative Model for the
 Management of Hypertension, Pharmacotherapy, Feb 2016

Buffington D, Wager D, McGann P
All In: Using Healthcare Collaboratives to Save Lives and Improve (Care, Spurlock &
 Teske), Chapter 4: "Key Elements of Effective Collaborative Design – Fostering
 Leadership at All Levels"
 2015

Buffington D (Contributing Author)
Medication Therapy Management: A Pharmacotherapy and Medication System
 Primer McGraw-Hill 2014

Buffington D
New Codes for Transitional Care Management and Chronic Care Coordination
 Services
 2012

Buffington D, Isetts B
Coding Principles for Medication Therapy Management Services: The ABCs of CPTs
 The Pharmacist's Guide to Compensation for MTM Services, Chapter 6, 2009

Buffington D
Future of medication therapy management services in delivering patient-centered
 care
 American Journal of Health-System Pharmacy, Sep 2007

Brill J, Buffington D, Downs C, Siegel
Perspectives one year after implementation of the Medicare Prescription Drug
 Improvement and Modernization Act: A Socratic Panel Discussion
 American Journal of Health-System Pharmacy, Sep 2007

Buffington D, Isetts B
CPT cod-change proposal: National data on pharmacists' medication therapy
 management services
 Journal of the American Pharmacists Association, Jul/Aug 2007, 491-495

Isetts, B, Cipolle R, Buffington D

Medication Therapy Management Relative Value Scale Survey Proposal

American Pharmacists Association, May 2007

Buffington D

Pharmacist current Procedural Terminology codes and medication therapy management

Medicare Modernization Act Q&A

American Journal of Health-System Pharmacists, Vol 63 Jun 2006

Buffington D

Coding Communication: Medication Therapy Management Services

American Medical Association, CPT Assistant, Apr 2006 / Volume 16, Issue 4

Rauck RL, Wallace M, Leong M, Minehart M, Webster L, Charapata S, Abraham J, Buffington D, Ellis D, Kartzinel R, et al

A Randomized, Double-Blind, Placebo-Controlled Study of Intrathecal Ziconotide in Adults with Severe Chronic Pain

Journal of Pain and Symptom Management, 2006; 31:393-406

Turner JL, Kosstman JR, Aquino A, Wright D, Szabo S, Bidwel RI, Goodgame J, Daigle A, Kelley E, Jensen F, Duggy C, Carlo D, and Moss RB

The effects of an HIV-1 immunogen (Remune) on viral load, CD4 cell counts and HIV-specific immunity in a double-blind, randomized, adjuvant-controlled subset study in HIV infected subjects regardless of concomitant antiviral drugs

HIV Medicine, Buffington D, Editorial Panel, Research Site, 2001 2, 68-77

Buffington D, et al

Participation as an Investigator in the IRC 806 Clinical Research Trial

JAMA, Feb 2001

Buffington D

Improving Our Communications Via the Internet

Florida Journal of Health-System Pharmacy, Volume 18, Number 3, Jan 2001

Buffington D, et al

Sparfloxacin for the treatment of acute bacterial maxillary sinusitis documented by sinus puncture

Annual Allergy Asthma Immunology, 2000; 84:63-71 Volume 84, Jan 2000

Poirier S, Buffington D, Memoli G

Billing Third Party Payers for Pharmaceutical Care Services

Annals of Allergy, Asthma and Immunology, Feb 1999

Buffington D, Garrison N, Spector S, Stafford C, Granito K, Zhang H, Talbot G

Sparfloxacin for the Treatment of Acute Bacterial Maxillary Sinusitis

Manuscript for Rhone-Poulenc Rorer, Nov 1997

Buffington D

Identifying Profitable Areas of Expansion: Obtaining Reimbursement

American Society of Health-System Pharmacists, Center on Pharmacy Practice Management, Oct 1997

Buffington D

Reimbursement for Pharmacy Services

Specialists Spectrum, ASHP, Vol.1, No.1, p.3, Fall 1994

Buffington D, Lampasona V, Chandler M.

Computers in Pharmacokinetics: Choosing Software for Clinical Decision Making

Clinical Pharmacokinetic, 25 (3):205-216, Oct 1993

Buffington D

Predict what major changes will result from health care reform. What impact will these changes have on you and how you conduct your business

Florida Journal of Hospital Pharmacists, Vol. 13, No. 4, p. 23, Aug 1993

Asbury WH, Darsey EH, Rose WB, Murphy JE, Buffington DE, Capers CC

Vancomycin Pharmacokinetics and Neonates in Infants: A Retrospective Evaluation

Annals of Pharmacotherapy, Apr 1993;27:490-6

Pritchard J, Buffington D

Is varicella immune globulin (VZIG) an appropriate therapy for the treatment of chicken pox

Florida Journal of Hospital Pharmacy, Vol. 13, No. 3, Jul 1993:29-30

Perkins J, Buffington D, Hoffman M

Gynecologic Malignancies (Chapter 120)

Pharmacotherapy (Second Edition)

Buffington D, Wallach P

Is methemoglobinemia associated with dapsone therapy?

Florida Journal of Hospital Pharmacy, Vol. 13, No. 1, Feb 1993:29

Morton T, Buffington D

Post-graduate pharmacy training programs in Florida

Florida Journal of Hospital Pharmacy, Vol. 13, No. 1, Feb 1993:29-31

Buffington D, Toney J

Focus on temafloxacin: A new rapidly absorbed, extended-spectrum fluoroquinolone antibiotic

Hospital Formula, Jan 1992:27:241-247

Buffington D

Injectable Nonsteroidal Anti-inflammatory: Alternative to Narcotics

Hospital News p. 16, Mar 1991

Buffington D

How is alfa interferon being used in the treatment of cancer?

Florida Society of Hospital Pharmacist Digest, Feb 1991

Buffington D

New medication helps protect the bladder during chemotherapy

Hospital News p. 19, Jan 1991

Buffington D

The Fluoroquinolones and Theophylline: A Potential for Interaction

Pharmacotherapy Forum Vol.1/No.1, Oct 1990

Buffington D

Word Processors and desktop publishing put shine on drug utilization reviews

Drug Utilization Reviews Vol.5/No.4, Apr 1989

Buffington D

Ticar7 and Timentin7: Recent Formulary Changes

EUH/Antibiotic Use Reviews, Oct 1987

Buffington D

Methicillin-Resistant Staphylococcus Aureus (MRSA)

DGH/Pharmacy News, May 1986

Gilmore R, Russell J, Buffington D

Legislative Review of Georgia's Third-Party Prescription Programs

Georgia Pharmaceutical Association, May 1986

Toler SM, Lopez AV, Buffington D

Smoking and the fetus - What You Should Know

Georgia Pharmaceutical Association Journal, (Computer Graphics)

RESEARCH PROTOCOLS:

2015

COV02520124: An Open-Label, Safety and Pharmacokinetic Study of Hydromorphone Hydrochloride Extended-Release Tablets (Once-Daily Hydromorphone) in Opioid-Tolerant Pediatric Subjects with Chronic Pain

2012

D3820C0005: A Randomized, Double-blind, Placebo-Controlled Study to Assess the Efficacy and Safety of NKTR-118 in Patients with Non-Cancer-Related Pain and Opioid-Induced Constipation (OIC)

2011

D3820C0004: A Randomized, Double-blind, Placebo-Controlled Study to Assess the Efficacy and Safety of NKTR-118 in Patients with Non-Cancer-Related Pain and Opioid-Induced Constipation (OIC)

GWCA0999: A multicenter, non-comparative, follow-on study to assess the long term safety of Sativex oromucosal spray (Sativex®; Nabiximols) therapy in patients with cancer related pain.

GWCA0958: A double blind, randomized, placebo-controlled, parallel group study of Sativex oromucosal spray (Sativex®; Nabiximols) in relieving pain in patients with advanced cancer, who experience inadequate analgesia during optimized chronic opioid therapy

2010

CQAB149B2223: A multi-center, randomized, double-blind, placebo controlled, parallel group, repeated-dose study to evaluate the efficacy, safety, tolerability and pharmacokinetics of three different dosing regimens of inhaled indacaterol maleate in patients with persistent asthma

GS-US-164-0216 The SWIFT Study: A Prospective, Randomized, Open-Label Phase IV Study to Evaluate the Rationale of Switching from Fixed-Dose Abacavir (ABC)/Lamivudine (3TC) to Fixed-Dose Tenofovir DF (TDF)/Emtricitabine (FTC) in Virologically-Suppressed, HIV-1 Infected Patients Maintained on a Ritonavir-Boosted Protease Inhibitor-Containing Antiretroviral Regimen

2009

The SWIFT Study: A Prospective, Randomized, Open-Label Phase IV Study to Evaluate the Rationale of Switching from Fixed-Dose Abacavir (ABC)/ Lamivudine (3TC) to Fixed-Dose Tenofovir DF (TDF)/Emtricitabine (FTC) in Virologically-Suppressed, HIV-1 Infected Patients Maintained on a Ritonavir-Boosted Protease Inhibitor-Containing Antiretroviral Regimen GS-US-164-0216

Blood Pressure and Metabolic Effects of Nebivolol Compared with Hydrochlorothiazide and Placebo in Hypertensive Patients with Impaired Glucose Tolerance or Impaired Fasting Glucose Protocol ID: NEB-MD-04

A double blind, randomized, placebo controlled, parallel group dose-range exploration study of Sativex® in relieving pain in patients with advanced cancer, who experience inadequate analgesia during optimized chronic opioid therapy GWCA0701

2005

An Open-Label, 12-Month Study to Evaluate the Safety, Tolerability, and Efficacy of ORAVESCENT® Fentanyl Citrate for the Management of Breakthrough Pain in Opioid-Tolerant Patients with Chronic Non-cancer Pain C25608/3040/BP/US (Cephalon)

A Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ORAVESCENT® Fentanyl Citrate for the Management of Breakthrough Pain in Opioid-Tolerant Patients With Chronic Neuropathic Pain C25608/3041/BP/US (Cephalon)

A Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ORAVESCENT® Fentanyl Citrate for the Management of Breakthrough Pain in Opioid-Tolerant Patients With Chronic Low Back Pain C25608/3042/BP/US (Cephalon)

Survey to Assess the Prevalence, Characteristics and Impact of Breakthrough Pain in Chronic Pain Patients with and without Cancer Managed by Clinicians Who are not Pain Specialists SMI05002

2004

THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF ACAM2000 SMALLPOX VACCINE IN ADULTS WITH PREVIOUS SMALLPOX VACCINATION. A Randomized, Double-Blind, Fixed Dose, Phase 3 Comparison between ACAM2000 and Dryvax® Smallpox VaccinesH-400-012 (Acambis)

A Multicenter, Phase 3 Study to Confirm the Safety and Efficacy of Intravenous Doripenem in Complicated Lower Urinary Tract Infection or Pyelonephritis DORI-06 (Peninsula Pharmaceuticals)

THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF ACAM2000 SMALLPOX VACCINE IN ADULTS WITHOUT PREVIOUS SMALLPOX VACCINATION. A Randomized, Double-Blind, Fixed Dose, Phase 3 Comparison between ACAM2000 and Dryvax® Smallpox VaccinesH-400-009 (Acambis)

An Open-Label, Long Term, Multi-Center, Intrathecal Ziconotide (PRIALT™) Effectiveness And Safety Trial (ZEST) In Patients With Chronic Severe Pain ELN92045-501

A Multi-Center, Open-Label, Long-Term Study of OraVescent® Fentanyl Citrate for the Treatment of Breakthrough Pain in Opioid-Tolerant Cancer Patients 099-15 (CIMA)

A Multi-Center, Double-Blind, Placebo-Controlled Study of OraVescent® Fentanyl Citrate for the Treatment of Breakthrough Pain in Opioid-Tolerant Cancer Patients 099-14 (CIMA)

2003

A multicenter, international, randomized, open-label, assessor-blind, non-inferiority study comparing the efficacy and safety of once-weekly subcutaneous SanOrg 34006 with the combination of (LMW)Heparin and vitamin K antagonist (VKA) in the treatment of acute symptomatic pulmonary embolism P64714 / EFC 3484 (Organon/Sanofi)

An Open-label, Multicenter Study of the Safety and Efficacy of Combined Intrathecal Infumorph and Ziconotide (Prialt): Addition of Infumorph in Patients Receiving Prialt for Severe Chronic Pain ELN92045-201 (Elan Pharmaceuticals)

A Double-Blind, Double-Dummy, Randomized, Placebo- and Active-Controlled, Multicenter, Parallel-Group Study of (R,R)-Formoterol in the Treatment of Subjects with Chronic Obstructive Pulmonary Disease 091-051 (Sepracor)

2002

A Phase III, Vehicle-Controlled Study of Topical Resiquimod (R-848) 0.01% Gel Applied 2 Times per Week for 1 Week for Each Recurrence of Anogenital Herpes over 52 Weeks Study 1452-RESI (3M Pharmaceuticals)

A Retrospective, Case-Control Study to Investigate Genetic Polymorphisms in HIV Infected Subjects Who Developed Hypersensitivity Following Treatment with Abacavir CNA30032 (GlaxoSmithKline)

Vehicle-Controlled, Double-Blind Study to Assess the Safety and Efficacy of Imiquimod 5% Cream Applied Once Daily 3 Days per Week for the Treatment of Actinic Keratoses on the Head 1447-IMIQ (3M Pharmaceuticals)

An Open-label, Long-term, Multicenter Study of Ziconotide Administered Intrathecally ELN92045-352 (Elan Pharmaceuticals)

A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF INTRATHECAL ZICONOTIDE IN ADULTS WITH SEVERE CHRONIC PAIN ELN92045-301 (Elan Pharmaceuticals)

AN OPEN-LABEL, LONG-TERM, MULTICENTER STUDY OF ZICONOTIDE ADMINISTERED INTRATHECALLY ELN92045-351, IND # 45,718 (Elan Pharmaceuticals)

A Case Control Investigation Exploring the Relationship Between Gene Variants (HAPTM Markers) and Agranulocytosis or Granulocytopenia In Adult Patients Treated With Clozapine

A 6-month open label, multi-national, effectiveness, and safety study of Elidel[®] (pimecrolimus) Cream, 1% in subjects with atopic dermatitis Novartis CASM981 C2405

2001

APV30001: A Phase III, randomised, multicenter, parallel, open-label study to compare the efficacy, safety and tolerability of GW433908 (1395mg bid) and Nelfinavir (1250mg bid) over 48 weeks in antiretroviral therapy naïve HIV-1 Infected Adults (Glaxo Welcome)

APV30005: An open-label phase III study to assess the long term safety profile of GW43398 containing regimens in HIV-1 infected subjects (Glaxo Welcome)

A Phase II, Randomized, Double-Blind, Vehicle-Controlled, Dose Frequency Response Study of Topical Resiquimod (R-848) Gel Applied to Anogenital Herpes Lesions Once, Twice or Three Times Per Week for One Recurrence to Prevent Future Recurrences 1411-RESI (3M Pharmaceuticals)

Vehicle-Controlled, Double-Blind Study to Assess the Safety and Efficacy of Imiquimod 5% Cream Applied Once Daily 3 Days per Week for the Treatment of Actinic Keratoses on the Head (3M Pharmaceuticals)

A prospective, randomized, double blind, multicenter trial assessing the safety and efficacy of sequential (intravenous/oral) BAY 12 -8039 (moxifloxacin) 400 mg every 24 hr compared to intravenous piperacillin/tazobactam 3.0/0.375 g every 6 hr followed by oral amoxicillin/clavulanic acid suspension 800 mg every 12 hr for the treatment of patients with complicated skin and skin structure infections (Bayer)

Protocol #: CPS 2000-01A An Open Label, Phase 1 Study of the Safety and Tolerability of Coccoleba uvifera in Healthy Volunteers

Omapatrilat Cardiovascular Treatment Assessment versus Enalapril (OCTAVE) Protocol Number: CV137-120

Protocol Number: CPS.USF.001 An Open Labeled, Single Blind, Patient-Controlled Study of the Safety and Efficacy of Clobetasol Propionate Foam, 0.05% in the Treatment of Alopecia Areata

CNA30021: A phase III, 48-week, randomized, double-blind, multicentre study to evaluate the safety and efficacy of abacavir (ABC) 600mg once-daily (QD) vs abacavir 300mg BID in combination with lamivudine (3TC) (300mg QD) and efavirenz (EFV) (600mg QD) in antiretroviral therapy naïve HIV-1 infected subjects (GlaxoSmithKline)

A Phase III, randomized, multicenter, parallel, open-label study to compare the efficacy, safety, and tolerability of GW433908 1395 mg bid and Nelfinavir 1250 mg bid over 48 weeks in antiretroviral therapy naïve HIV-1 Infected Adults (Glaxo)

A Multicenter Dose Randomized Evaluation of Targretin® Capsules + PUVA In Patients With Stage IB – IIA Cutaneous T-Cell Lymphoma IND No. 61,896 (Ligand)

A Multicenter, Randomized, Open-Label Study Comparing the Efficacy And Safety Of Once Daily (OD) ORG 31540/SR90107A Versus Adjusted-Dose Intravenous (IV) Unfractionated Heparin (UFH) In The Initial Treatment Of Acute Symptomatic Pulmonary Embolism (PE) (Organon)

Protocol Number: 25000/592. An Open, Non-Comparative Multicenter Study to Assess the Efficacy and Safety of Oral Augmentin® SR 2000/125 mg Twice Daily for 10 Days in the Treatment of Acute Bacterial Sinusitis in Adults (Smith-Kline Beecham)

VER001-5: Phase II Pilot, Randomized, Open-Label, Multi-center Study to Evaluate the Safety and Efficacy of Dalbavancin (V-Glycopeptide) Versus Investigator/Physician Designated Comparator in Skin and Soft Tissue Infection IND # 60,613 (Vericor)

2000

A Phase III, Multicenter, Randomized, Parallel Group, Evaluator Blinded, Comparative Study to Evaluate the Effectiveness and Safety of "Topical Otic CILODEX™ (ciprofloxacin 0.3%, dexamethasone 0.1%) Suspension Compared to CILOXAN® (ciprofloxacin 0.3%) Solution and CORTISPORIN® Suspension (neomycin 0.35%, polymyxin 10,000 IU/mL, hydrocortisone 1.0%) for Treatment of Patients with Moderate to Severe Acute Otitis External

1999

Protocol Title: Safety and Efficacy of Intravenous HMR4396 and Epogen® for the Management of Anemia in Subjects with Chronic Renal Failure Requiring Hemodialysis HMR4396A/3001

An Open-Label, Long-Term Safety and Tolerability Study of Ziconotide® Administered Intrathecally to Patients with Chronic, Severe Pain (Elan Pharmaceuticals)

1998

A One-Year Randomized, Double Blind, Placebo Controlled Study of Alosetron (GR68755) 1mg BID in Female Subjects with Irritable Bowel Syndrome S3B30006

A Open, Non-Comparative Multicentre Study to Assess the Efficacy and Safety of Oral Augmentin SR 2000/125 mg, Twice Daily for 10 Days in the Treatment of Acute Bacterial Sinusitis in Adults, Protocol BRL-02500/551 (Smith-Kline Beecham)

1997

A Multicenter, Double-Blind, Phase III, Adjuvant-Controlled Study of the Effect of 10 units of HIV-1 Immunogen Compared to IFA Alone Every 12 Weeks on AIDS-Free Survival in Subjects with HIV Infection and CD4 T Lymphocytes Between 300-549 cells mcg Regardless of Concomitant HIV Therapies Protocol IRC-806 (Immune Response Corporation)

A Randomized, Double Blind, Placebo Controlled, Efficacy and Safety Study of Oral Lobucavir In Patients With Recurrent Herpes Labialis, AI459-012 (Bristol-Myers Squibb)

A Randomized, Double Blind, Placebo Controlled, Efficacy and Safety Study of Oral Lobucavir In Patients With Recurrent Genital Herpes, AI459-011 (Bristol-Myers Squibb)

Phase II Multi-Center, Randomized, Placebo-Controlled, Two-Step Dose-Escalation Safety, Tolerability, and Hypothesis Generating Trail of Recombinant Tissue Factor Pathway Inhibitor (rTFPI), SC-59735 in Sepsis Patients, Protocol CS-TF004 (Chiron)

1996

A Randomized, Double-Blind, Multicenter Trial Assessing the Safety and Efficacy of a Single Intravenous Dose of CP-116,517 (alatrofloxin) Compared with Cefotetan for the Prophylaxis of Infection Following Colorectal Surgery #154-128 (Pfizer Central Research)

1995

Pfizer 154-128 Colo-Rectal Prophylaxis (Pfizer)

Pfizer 154-124 Intraabdominal Infections (Pfizer)

Matrix 66-94-2 5 FU/epi Basal Cell Carcinoma (Matrix)

RPR 106972 Streptogramin Sinusitis (Rhone-Poulenc Rorer)

Oral Cefpodoxime Proxetil (Vantin®) Tablets in the Treatment of Acute Maxillary Sinusitis in Adults #M/116/40/0108. (Upjohn Company)

A Double Blind, Comparative Study of the Efficacy and Safety of Orally Administered OPC-17116 and Clarithromycin in the Treatment of Patients with Community Acquired Pneumonia #106-94-206 (Otsuka America Pharmaceuticals, Inc.)

A Prospective, Randomized, Double-Blind, Parallel, Control, Multicenter Trial Comparing The Efficacy and Safety of 1% terbinafine (Lamisil®) Cream Applied Once Daily to Placebo In The Treatment of Cutaneous Candidiasis SFC-352 (Sandoz Pharmaceuticals)

1994

Multicenter, Randomized, Partially-Blind, Parallel Group, Clinical Trial to Compare the Efficacy and Safety of Twice and Once Daily Subcutaneously Administered Enoxaparin and Continuous Infusion Heparin in the Treatment of Patients with Deep Vein Thrombosis and Pulmonary Embolism RP-54536-529 (Rhone-Poulenc Roher)

Multicenter, Double Blind, Comparative Study of Intravenous meropenem (Merrem®) and imipenem (Primaxin®) for the Treatment of Nosocomial Lower Respiratory Tract Infections 359IL/0059 (Zeneca Pharmaceuticals)

Open, Non-comparative, Multicenter Study of RP64206 sparfloxacin in the Treatment of Acute Bacterial Maxillary Sinusitis RP64206-359 (Rhone-Poulenc Roher)

A Double-Blind, Parallel Group, Randomized Trial to Compare the Efficacy and Safety of Enoxaparin 40mg SC QD and Unfractionated Heparin 5000 IU SC TID During 6-12 Days for Prevention of Deep Vein Thrombosis (DVT) in 800 Evaluable Patients After Planned Elective Curative Cancer Surgery RP-54563-567 (Rhone-Poulenc Roher)

A Double-Blind Multinational Trial Comparing Sorivudine (BV-araU) (SQ 32,756) vs. Acyclovir for the Treatment of Acute Localized Herpes Zoster and the Effect on Zoster-associated Pain In Immunocompetent Subjects. BMS-AI458-072-008 (Bristol Myers Squibb)

Assessment and Analysis of Risk Factors for the Development of Candidemia in Hospitalized Patients, (Pfizer)

1993

Pharmacoeconomic Analysis of Systemic Antifungal Prescribing Patterns. (Pfizer/Roerig)

A Multicenter, Double-Blind Comparative Study of Intravenous Merrem (Meropenem) and Primaxin (imipenem-cilastatin) for the Treatment of Intra-Abdominal Infections. (Zeneca)

A Multicenter, Double-Blind Comparative Study of Intravenous Merrem (Meropenem) and Primaxin (Imipenem-Cilastatin) for the Treatment of Nosocomial Lower Respiratory Tract Infections (Zeneca)

Double Blind, Placebo-Controlled Study of the Efficacy and Safety of three doses of CP-127 and Placebo in Patients with Presumed Sepsis and the Systemic Inflammatory Response Syndrome (SIRS) CP-0127-92-002 (Cortech, Inc)

Double Blind, Randomized, Comparative Study of RP-64206 (Sparfloxacin) vs. Cefaclor in the Treatment of Community-Acquired Pneumonia (Rhone-Poulenc Rorer)

A Randomized, Double Blind, Placebo-Controlled, Multicenter Study of Oral GR122311X Compared with Ranitidine and GR88502X for the Prophylaxis of Nonsteroidal Anti-Inflammatory Drug Associated Gastric or Duodenal Ulcers in Patients with Osteo- or Rheumatoid Arthritis and without a History of Gastric or Duodenal Ulcers (Glaxo)

Prospective, Randomized, Third Party-Blind, Study to Compare the Safety and Efficacy of Ciprofloxacin (Sequential IV/PO) with Intravenous Ceftazidime and Tobramycin in the Treatment of Pediatric Cystic Fibrosis Patients with Acute Pulmonary Exacerbation D91-024, BAY o9867m BAY q3939 (Miles, Inc)

A Multicenter, Open-Label Treatment Protocol to Provide Aerosolized rhDNase Therapy to Patients with Cystic Fibrosis. rhDNase Protocol Z0507g-A2 (Genetech)

A Multicenter Epidemiologic Protocol to Evaluate Pulmonary Function and the Rate of Respiratory Tract Infections in Patients with Cystic Fibrosis rhDNase Z0525n (Genetech)

Lorabid, 200 mg vs. 400 mg BID in Sinusitis with Bacteriology. Lorabid Protocol B9U-MC-AZBX(b) IND No. 29957, NDA No. 50-668 (Eli Lilly)

Uncomparative Study of Sparfloxacin in Acute Sinusitis (Rhone-Poulenc Rorer)

1992

Comparison of the Safety and Efficacy of Cefodizime versus Ceftriaxone in the Treatment of Complicated Urinary Tract Infections. Cefodizime CSZ-300 (Fujisawa Pharmaceutical Corporation)

A Multicenter, Double-blind, Randomized, Comparative Study of the Efficacy and Safety of Temafloxacin Intravenous/Oral Sequential Therapy Versus Cefuroxime with or without Erythromycin Intravenous/Oral Sequential Therapy in the Treatment of Hospitalized Patients with Community Acquired Pneumonia. Temafloxacin #M91-651. (Abbott Laboratories)

A Phase III, Multicenter, Double-Blind, Placebo-Controlled, Parallel Study to Evaluate the Safety and Efficacy of Aerosolized Recombinant Human DNASE I (rhDNase) in Patients with Cystic Fibrosis (Genentech, Inc.)

Centocor: HA-1A™ Efficacy in Septic Shock Trial CHES #C0041T20 (Centocor, Inc.)

A Randomized, Double-Blind Repeat-Dose Crossover Study to Determine the Safety and Efficacy of sustained Versus Immediate Release Codeine Sulfate on Chronic Cancer Pain. Codeine #CSR-0192 (Roxane Laboratories)

A Randomized, Double-Blind Comparative Study of the Safety and Efficacy of Sustained Versus Immediate Release Codeine Sulfate in the Treatment of Chronic Cancer Pain. Codeine #CSR-0292 (Roxane Laboratories.)

A Multicenter Randomized, Double Blind, Placebo-Controlled Evaluation of Healing and Relapse Rates Following Oral GR122311X Compared with GR88502X, Ranitidine and Placebo in Patients with Duodenal Ulcer. Ranitidine #H2B-302 (Glaxo, Inc.)

A Multicenter Randomized, Double-Blind, Placebo-Controlled Evaluation of Healing and Relapse Rates Following Oral GR122311X Compared with GR88502X, Ranitidine and Placebo in Patients with Benign Gastric Ulcer. Ranitidine #H2B-312 (Glaxo, Inc.)

A Multicenter, Open-Label Treatment Protocol to Provide Aerosolized rhDNase Therapy to Patients with Cystic Fibrosis (Genentech, Inc.)

Prospective, Double Blind, Controlled, Randomized, Multi-Center Comparison of the Safety and Efficacy of Intravenous Ciprofloxacin Versus Intravenous Imipenem for the Treatment of Patients with the Sepsis Syndrome (Miles, Inc.)

RENOVA for the Treatment of Photo damaged Skin (Ortho Pharmaceuticals)

A Multicenter, Controlled Evaluation of the Safety and Efficacy of Repeated Oral Doses of Vicoprofen (hydrocodone bitartrate with ibuprofen) for the Treatment of Chronic Pain. Vicoprofen VP-04 IND No. 29498 (Knoll Pharmaceuticals)

1991

A Prospective Comparison of Ondansetron (IV) and Dexamethasone (PO) Versus Prochlorperazine (PO) and Dexamethasone (PO) for the Prevention of Post Chemotherapy Related Nausea and Vomiting

A Comparative Study of the Safety and Efficacy of BIOLID versus EES in the Treatment of Group A Beta-Hemolytic Streptococcal Pharyngitis. BIOLID BE-C200 (Belmac Corporation)

1989

A Randomized, Prospective, Comparative Study of the Efficacy of Cefoperazone/Sulbactam Versus Ceftazidime Plus Vancomycin Versus Ticarcillin Plus Gentamicin in Febrile Neutropenic Patients. Cefoperazone/Sulbactam 88-S-137. (Pfizer)

1988

An Open, Prospective Study to Evaluate the Incidence of Prothrombin Time Elevation and Clinical Bleeding in Patients Receiving One of Ten Selected Antibiotics. PT Elevation 88-R-041. (Pfizer Pharmaceuticals)

Imipenem-Cilastatin Efficacy, Tolerability and Economic Comparisons to Combination Antibiotic Therapy. Imipenem-Cilastatin.

A Comparison of Ampicillin/Sulbactam Versus Cefoxitin in the Prevention of Infections Complicating Radical Abdominal Hysterectomy. Ampicillin/Sulbactam 87-S-421. (Pfizer Pharmaceuticals)

Evaluation of Antibiotic Prophylaxis in Open Heart Surgery.

A Study of the Cost of Administration of Vancomycin and a Comparison with Alternative Antibiotic Therapy. Vancomycin. (Merrell Dow Pharmaceutical, Inc.)

1987

Evaluation of Gentamicin Levels Obtained from Hickman Catheters in a Hematology Population. Hickman Catheters HIC-118-87

PRESENTATIONS:

- | | |
|----------|--|
| 03-05-19 | Pharmacist-guided Exemplary Opioid Management Practices
WebEx Presentation
Tampa, FL |
| 11-28-18 | (INSERT TITLE)
PHIT Nov 28th CC Meeting & FYI Guiding Principles for the Development and Use of Documentation and Billing Codes for Pharmacists' Patient Care Services
Washington, DC |
| 09-12-18 | Prescription Drug Monitoring Programs
The Opioid Safety Project American Medical Association
PDMP
Opioid Webinar Lecture Series |
| 08-04-18 | Florida Society of Health-System Pharmacists Association 52 nd
Annual Meeting – Leadership Track
Orlando, FL |
| 05-09-18 | Advanced Practice Models: Transitions of Care
American Society of Consultant Pharmacist
Tampa, FL |
| 07-28-17 | DUI: Extrapolation, Medical v. Legal Draws, etc.
Florida Public Defender Association, Summer Training Program
Bonita Springs, FL |
| 07-13-17 | Innovations in Pharmacy Practice
Florida Pharmacy Association, 127th Annual Meeting and Convention
Orlando, FL |

07-01-17	Health Choice Network's 23rd Annual Educational Conference [insert title] Boca Raton, FL
04-24-17	Pharmacy Deans' Forum [insert title] National Association of Chain Drug Stores Annual Meeting Scottsdale, AZ
04/19-17	Emerging Payment Models for Physicians: What Does it Mean for AMCP Members and Medication Management? Academy of Managed Care Pharmacy Webinar Presentation
03-25-17	Creating a Successful Specialty Pharmacy American Pharmacists Association Annual Meeting San Francisco, CA
03-16-17	Medication Therapy Management (MTM), Clinical Research, and Forensic Pharmacy University of South Florida Pharmacy Skills Lecture (Clinical & Forensics) Tampa, FL
03-14-17	2017 Florida Pharmacists Legislative Days and Health Fair Pharmacy Advocacy Efforts [insert title] Tallahassee, FL
02-18-17	Kappa Psi Ideals: How They Can Shape Your Future and Ensure Your Success Keynote Speaker Kappa Psi Spring Assembly Tampa, FL
02-01-17	Pharmacy HIT Collaborative Council Face to Face Meeting American Pharmacist's Association [insert title] Washington, DC
01-26-17	Current Issues/Advocacy – Pharmacy Reimbursement Shenandoah University Winchester, VA
10-25-16	Keynote Speaker FSHP Mentor Dinner University of South Florida Tampa, FL
10-13-16	Provider Status Update Hillsborough County Pharmacist Association Tampa, FL
10-03-16	Making Your Goals a Reality Mentoring Hour and Leadership Presentation University of South Florida Tampa, FL

- 08-12-16 **Keynote Speaker**
Larkin Health Sciences Institute, College of Pharmacy
White Coat Ceremony
Miami, FL
- 06-30-16 **Pharmacy Practice Update: CMS Update and Reimbursement**
Florida Pharmacy Association
Ft. Lauderdale, FL
- 06-24-16 **Establishing and Paying for New Models of Pharmacy Care**
Medical College of Wisconsin, College of Pharmacy
Milwaukee, WI
- 02-01-16 **USF AMCP Student Group Lecture**
Tampa, FL
- 02-20-16 **Pharmacist's Reimbursement: Current and Future Trends**
American Association of Colleges of Pharmacy
Tampa, FL
- 02-11-16 **National Progress Toward a Health System that Supports Pharmacist Clinical Services**
The 3rd USC Conference on Optimizing Medication Safety and Healthcare Quality: Best Practices and Collaborations for Public Health, Geriatrics, and Mental Health
University of Southern California
Los Angeles, CA
- 08-12-15 **U.S. Healthcare Reform and Its Impact on Pharmacy Practice**
University of South Florida, College of Pharmacy
Tampa, FL
- 08-09-15 **Ask the Experts Panel: Provider Status**
Florida Society of Health-System Pharmacists Association
Orlando, FL
- 08-09-15 **MTM Services with a focus on Provider**
Florida Society of Health-System Pharmacists Association
Orlando, FL
- 06-26-15 **Profession & Career Planning: Expanding Your Horizons**
Florida Pharmacy Association 2015 Annual Meeting
St. Augustine, FL
- 04-18-15 **Medicare & Health Care Reform: Opportunities for Pharmacists**
Florida Pharmacy Association Law and Regulatory Conference
Tampa, FL
- 03-16-15 **Recognizing Pharmacists as Providers: Expanding Scope of Practice**
South Carolina Society of Health-System Pharmacists Annual Meeting
Hilton Head Island, SC
- 02-21-15 **Pharmacists Influencing Positive Health Outcomes**
Virginia Pharmacist's Association Midyear Meeting
34th Annual Rooke Award Lecture
Roanoke, VA

- 01-10-15 **Defining Your Path as Leaders... Oh the Places You'll Go!**
Florida Pharmacy Association Leadership Conference
Orlando, FL
- 12-06-14 **What is Pharmacist Provider Status and Why Is It Necessary**
Florida Pharmacy Association Law and Regulatory Conference
Sarasota, FL
- 11-06-14 **Protecting Your Patient and Yourself: Universal Precautions, the Pharmacist, and Ebola**
American Society of Consultant Pharmacists (SCP) 2015 Annual Meeting
Orlando, FL
- 08-25-14 **Future of Pharmacy Curricula: Blending Clinical & Entrepreneurial Skills**
University of Virginia College of Pharmacy, Visiting Faculty
Virginia Commonwealth University School of Pharmacy
Richmond, VA
- 07-10-14 **Innovative Health Care Solutions: The Impact of Integrating Pharmacist's Services**
124th Annual Florida Pharmacy Association Meeting
Ft. Lauderdale, FL
- 12-07-13 **Update on the Provider Status and MTM Reimbursement**
Florida Pharmacy Association
Regulatory and Law Conference
Sarasota, FL
- 09-08-13 **Update on the Provider Status and MTM Reimbursement**
Florida Pharmacy Association
Regulatory and Law Conference
Ft. Lauderdale, FL
- 07-13-13 **Florida Healthcare Law Update**
University of Florida, College of Pharmacy
FPA Gator Reception
Orlando, FL
- 07-13-13 **MTM Practice Models and CPT Coding Update**
123rd Annual Meeting and Convention
Florida Pharmacy Association
Orlando, FL
- 05-03-13 **Medicare Provider Status for Pharmacists**
University of Florida, College of Pharmacy
Spring National Advisory Board Meeting
Orlando, FL
- 04-04-13 **Employer-based Initiatives: Role of the Pharmacists in Transition of Care.**
Transition of Care & Readmissions Boot Camp
36th Annual Conference, Survive and Thrive in the Changing Health Care Environment
American Board of Quality Assurance & Utilization Review Physicians (ABQAURP)
Tampa, FL

- 03-22-13 **The Future of Pharmacy: Your Vision, Your Plan?**
National Student Pharmacist Compounding Competition,
University of Florida College of Pharmacy
Gainesville, FL
- 03-23-13 **MTM Coding: Current Procedural Terminology**
National Student Pharmacist Compounding Competition,
University of Florida College of Pharmacy
Gainesville, FL
- 11-03-12 **Strategic Positioning of MTM Services and Reimbursement in
HealthCare Reform**
Nova Southeastern University
Ft. Lauderdale, FL
- 07-20-12 **Medication Therapy Management: Emerging Payment Options**
Georgia Society of Health-System Pharmacists
2012 Summer Meeting
Amelia Island, FL
- 06-24-12 **Compensation for MTM Services: Where We've Been
And Where We're Going**
American Pharmacist's Association
MTM Emerging Opportunities (McKesson Meeting)
Las Vegas NV
- 3-31-12 **Opiate Metabolism: Dangerous Interactions**
Prescribing in an Epidemic – Uniting Medical, Legal &
Corporate Entities in Fighting America's Deadly Epidemic
Gulf Stream, FL
- 03-10-12 **Compensation for MTM Services: Where We've Been and Where
We're Going**
American Pharmacist's Association Annual Meeting 2012
New Orleans, LA
- 02-16-12 **Overview CDTM with metrics Measurement-Inpatient and
Ambulatory Practice**
CDTM Summit
New York State Council of Health-system Pharmacists
Albany, NY
- 10-17-11 **ACCP Meeting**
Challenges to Expanding the Scope of Clinical Pharmacy
Pittsburgh, PA
- 10-17-11 **Challenges to Expanding the Scope of Clinical Pharmacy**
American College of Clinical Pharmacy Annual Meeting
Pittsburgh, PA
- 08-27-11 **Prescribing in an Epidemic**
Associates in Emergency Medical Education
Tampa, FL
- 05-26-11 **Collaborative Drug Therapy Management as a Tool for
Medication Therapy Management**
34th Annual Schwarting Symposium Presentation
Hartford, CT

- 12-4-10 **Developing ED practice models to ASHP
Emergency Medicine PRN**
45th Annual Midyear Meeting
Anaheim, CA

- 09-18-10 **Healthcare Reform Update**
Central Florida Society of Health-System Pharmacists
Orlando, FL

- 07-17-10 **Summer Seminar**
University of Florida
Tampa, FL

- 04-28-10 **Therapy Management: Rheumatology and High Cost Agent**
Lake Erie College of Osteopathic Medicine (LECOM)
Bradenton, FL

- 02-26-10 **The Current Healthcare Environment: Where Does Medication
Therapy Management Fit it?**
Florida A & M University
33rd Annual Clinical Pharmacy Symposium
Tallahassee, FL

- 12-09-09 **Educating Patients about Gene Therapy: Information and Tools**
44th Annual Midyear meeting
American Society of Health-System Pharmacists
Las Vegas, NV

- 12-08-09 **Submitting Medical Service Claims for Pharmacists' Clinical
Activities**
44th Annual Midyear meeting
American Society of Health-System Pharmacists
Las Vegas, NV

- 11-06-09 **Medication Therapy Management and CPC codes for
Reimbursement**
University of Florida COP 2009 Dean's National Advisory Board
Meeting
Gainesville, FL

- 09-25-09 **Journal Club Session**
University of Florida Fall Faculty Workshop Conference
Orlando, FL

- 09-19-09 **Pharmacy Managed Hyperlipidemia Clinic: Practice Models
and Payment Mechanisms for Clinical Services**
Southwest Florida Society of Health-System Pharmacy
Tampa, FL

- 07-31-09 **Reaching Milestones MTM**
Florida Society of Health-System Pharmacists
43rd Annual Meeting
Orlando, FL

- 07-11-09 **Pharmacy Managed Hyperlipidemia Clinic: Practice Models
and Payment Mechanisms for Clinical Services**
Florida Pharmacy Association 119th Annual Meeting and
Convention
St. Augustine, FL

- 02-24-09 **Medication Therapy Management, Documentation and Marketing**
Lake Erie College of Osteopathic Medicine (LECOM)
Bradenton, FL
- 01-15-09 **The Profession's Perspective on MTM Documentation and Billing in Providing Effective and Efficient Patient Care**
2009 Annual Industry & Technology Issues Conference
American Society for Automation in Software (ASAP)
St. Petersburg, FL
- 12-9-08 **AMA-CPT Code Development and Update**
2008 ASHP Management Pearls
Orlando, FL
- 12-05-08 **Medication Therapy Management: Getting Paid for Clinical Services**
University of Florida Seminar Presentation
Gainesville, FL
- 11-14-08 **Medication Therapy Management: Getting Paid for Clinical Services**
Keynote Speaker, 2008 Michigan Society of Health-System Pharmacists Annual Meeting
Lansing, MI
- 10-07-08 **Documentation & Billing Standardization**
2008 APHA Foundation Conference
Bethesda, MD
- 09-12-08 **Design and Management of Medical Journal Club**
2008 University of Florida, College of Pharmacy, Dean's Counsel Symposia
Orlando, FL
- 08-25-08 **Medication Therapy Management: What's Next for Community Pharmacy?**
2008 National Association of Chain Drug Stores Pharmacy & Technology Conference
San Diego, CA
- 07-10-08 **The MTMS Business Plan and Dealing with Legal Billing Issues**
Florida Pharmacy Association
Orlando, FL
- 06-08-08 **ASHP Summer Meeting**
Seattle, WA
- 04-12-08 **Strategies for Optimal Therapy in High Risk Patients: Treatment of COPD, Acute Coronary Syndrome & Venous Thromboembolism**
Florida Chapter of American Society of Consultant Pharmacists Senior Care 2008
Tampa, FL

- 04-7-08 **Determining the value of Pharmacy Services and Interventions in the ambulatory care setting**
American College of Clinical Pharmacy
2008 Spring Practice and Research Forum
Phoenix, AZ

- 03-16-08 **Documenting MTM and Patient Care Activities**
APhA 2008 Annual Meeting
San Diego, CA

- 02-09-08 **A Vision for the Future: Developing Pharmacy Practice Models**
Pennsylvania Pharmacists Association 2008 Mid Year Meeting
Harrisburg, PA

- 10-14-07 **Development of Pharmacist Professional Services: The Future of MTMS**
NCPA 109th Annual Convention
Anaheim, CA

- 09-20-07 **Software, Documentation and Billing**
National Association of Chain Drug Stores Meeting, Medication Therapy Management Services in Community Pharmacy: Building Process, Partnerships, and Outcomes
Philadelphia, PA

- 06-26-07 **Current Legislative and Regulatory Issues in Pharmacy 2007**
American Society of Health-system Pharmacists – Summer Meeting
San Francisco, CA

- 05-22-07 **General Session: Perspectives in Practice: Medication Therapy Management Services**
American Society of Consultant Pharmacists 29th Midyear Conference
Hollywood, FL

- 05-22-07 **Business Skills 101: Contracting to Provide MTM Services**
American Society of Consultant Pharmacists 29th Midyear Conference
Hollywood, FL

- 12-2/4-06 **Impact of the Medicare Modernization Act on Pharmacy Reimbursement: Lessons Learned at the One Year Benchmark**
American Society of Health-system Pharmacists – Midyear Meeting
Anaheim, CA

- 11-20-06 **PQA National Meeting**
American Society of Health-system Pharmacists
Washington, DC

- 11-18/20-06 **Purchasing Medications Through the Internet**
CDMI – Pfizer
Chicago, IL

- 11-16-06 **Understanding CPT Codes**
American Society of Consultant Pharmacists
37th Annual Meeting and Exhibition - Senior Care Pharmacy
Phoenix, AZ

- 11-16-06 **Defining Your Professional Services**
American Society of Consultant Pharmacists
37th Annual Meeting and Exhibition - Senior Care Pharmacy
Phoenix, AZ
- 10-28-06 **Pharmacy Perspective on Quality Issues**
29th Annual Health Care Quality and Patient Safety
Conference Quality: The Pathway to Success
American Board of Quality Assurance & Utilization Review
Physicians
Chicago, IL
- 10-27-06 **Models of Delivery for Patient Care – Future of MTMS**
American College of Clinical Pharmacy
29th Annual Health Care Quality & Patient Safety Conference
Quality: The Pathway to Success
St. Louis, MO
- 10-19-06 **Effective Oncology Benefit Management**
Center for Business Intelligence's Effective Oncology Benefit
Management Conference
Chicago, IL
- 09-29-06 **Pharmacist Service Payment: Blueprint for Success**
Alabama Pharmacy Consensus Conference
Auburn University Harrison School of Pharmacy
Auburn, AL
- 09-20-06 **Opportunities to Implement Compliant MTMP**
HCPro
Online Audio Conference
- 07-09-06 **CPT Coding**
Georgia Society of Health-System Pharmacists
2006 Summer Meeting
Amelia Island, FL
- 05-15-06 **MTM – Focus Presentation**
FMQAI Presentation
Tampa, FL
- 05-05-06 **Emerging Trends in Clinical Medical Management: Value of
Pharmacists Services**
American Board of Quality Assurance & Utilization Review
Physicians (ABQAURP), Medical Management System
Innovations: The Next Generation
Orlando, FL
- 04-28-06 **Pharmacist/Physician Collaboration Strategies**
Walgreen's National Advisory Board Meeting
Rosemont, IL
- 04-27-06 **Medicare Part D and the Expanding Need for Pharmacists
Services**
Pharmacy Society of Wisconsin
Madison, WI

- 04-24-06 **Value of Psychiatric Medicine Debate – Industry and Managed Care Perspectives**
College of Psychiatric and Neurologic Pharmacists (CNCP)
Annual Meeting 2006
Baltimore, MD
- 04-22-06 **Medicare Part D: The Pharmacist's Role in Patient Management**
National Advisory Board
University of Florida College of Pharmacy
Gainesville FL
- 04-07-06 **Pharmacists Billing Codes: Application in Practice Models**
AMCP 18th Annual Meeting and Showcase
Seattle, WA
- 04-05-06 **Medicare Part D: Prescription Drug Plans and MTMS Benefit Design**
Academy of Managed Care Pharmacy (AMCP)
18th Annual Meeting & Showcase
Seattle, WA
- 03-23-06 **Medicare/CPT/Hospital**
Catholic Health Partners
Cincinnati, OH
- 02-26-06 **Medicare Reimbursement of Drug Therapy Management**
Tennessee Society of Health –System Pharmacists (TSHP)
Midyear Seminar
Nashville, TN
- 02-20-06 **University of South Carolina**
University of South Carolina College of Pharmacy (USC COP)
Rho Chi Society Banquet,
Columbia, SC
- 02-17-06 **Medication Therapy Management Services: Opportunities for Pharmacists and Implications for Treatment Options**
American Society of Consultant Pharmacists
2006 Spring Meeting, Hilton Clearwater Beach Resort
Clearwater, FL
- 01-28-06 **Update on Medicare Part D and CPT Codes for Pharmacists' Services**
Iowa Pharmacy Association
Educational Expo 2006
Des Moines, IA
- 01-25-06 **Update on Medicare Part D and CPT Codes for Pharmacists' Services**
Pinellas County Pharmacy Association Meeting
Hospice of the Florida Suncoast
Clearwater, FL
- 12-06-05 **Practice Applications in Medication Therapy Management Services (MTMS) in Medicare Part-D**
American Society of Health-System Pharmacists
Midyear Meeting (ASHP)
Las Vegas, NV

- 12-05-05 **Cutting-Edge Ambulatory Practice Program**
American Society of Health-System Pharmacists
Midyear Meeting (ASHP)
Las Vegas, NV
- 12-03-05 **Impact of Medicare Part D and MTMS on Anticoagulation Services**
20th Anniversary of the Pharmacy Invitational Conference on Antithrombotic Therapy (PICAT), Tuscany Suites and Casino
Las Vegas, NV
- 12-03-05 **Selective Issues in Hospital Pharmacy Practice for 2006: Medicare Part D – It's Here!**
University Health-System Consortium, Pharmacy Council
Las Vegas, NV
- 12-03-05 **Anticoag**
ASHP Midyear Meeting
Las Vegas, NV
- 11-15-05 **Electronic Billing of Non-Dispensing Pharmacy Services**
National Association of Chain Drug Stores (NACDS) 2005 Pharmacy & Technology Conference
San Diego, CA
- 11-12-05 **Clinical Pharmacy Interventions Post MMA**
American Society of Consultant Pharmacists, Senior Care Pharmacy '05 (ASCP)
36th Annual Meeting Exhibition Course Tracking/Publishing #20-39948/10-231316
Boston, MA
- 10-26-05 **MMA and Medicare Part D**
AmeriDrug & JSA Medical Group
Tampa, FL
- 09-29-05 **MTMS Presentation**
Florida Hospital Presentation & Consulting
Orlando, FL
- 09-26-05 **MMA and Medicare Part D**
NCPDP Educational Summit
Countdown to MMA: New & Unfinished Business
San Diego, CA
- 09-15-05 **Pharmacist-Based CPT Codes for Medication Management**
The Profession has been recognized with CPT Codes, What Next?
ASHP Teleconference Seminar
- 08-31-05 **Electronic Billing of Non-Dispensing Pharmacy Services**
National Association of Chains Drug Stores Foundation (NACDS) 2005 Pharmacy & Technology Conference
San Diego, CA
- 08-16-05 **Current Opportunities in Billing for Pharmacist Clinical Services**
National Council of Prescriptions and Drug Programs (NCPDP) Educational Summit, Countdown to MMA: New and Unfinished Business
Philadelphia, PA

- 08-06-05 **Using a PDA to Demonstrate the Value of Clinical Pharmacy Services**
Florida Society of Health-System Pharmacists (FSHP)
39th Annual Meeting, Gaylord Palms Resort and Convention Center
Orlando, FL
- 08-02-05 **MTMS Medicare Part D**
Keystone Medical
Philadelphia, PA
- 07-08-05 **Medicare Modernization Act: What we need to Know on January 1, 2006**
Florida Pharmacy Association (FPA)
115th Annual Meeting and Convention
Marco Island, FL
- 06-23-05 **Show me the Money: Billing & Payment for MTM**
National Association of Chain Drug Stores Foundation
Washington, DC
- 06-16-05 **Develop a Clinical Practice**
Arizona Pharmacy Association (AZPA)
1st Annual Meeting
Phoenix, AZ
- 06-16-05 **Update on Medication Therapy Management Services (MTMS) and Medicate Part D**
Tampa Bay Residency Forum, St. Bart's Island House
Tampa, FL
- 05-01-05 **How to Start a Clinical Practice**
Arizona Pharmacy Association
1st Annual Convention, Wild Horse Pass Resort ND Spa
Chandler, AZ
- 04-30-05 **Tip Jars for Pharmacists: Current Update on Pharmacist Reimbursement Trends**
Nova Southeastern University (NSU)
16th Annual Program Contemporary Pharmacy Issues
Davie, FL
- 04-11-05 **Current Opportunities in Billing and the Medicare Drug Benefit**
American College of Clinical Pharmacy (ACCP)
2005 Spring Practice Research Forum/Updates in Therapeutics
Myrtle Beach, FL
- 04-02-05 **Development of Current Procedural Terminology (CPT) Codes for Pharmacists Services: Implications for Residency Training Programs**
American Pharmacists Association Community Pharmacy Residency Program (CPRP)
Annual Meeting 2005
Orlando, FL
- 02-15-05 **Value of Medicine**
Diagnostic Clinic of Largo
Largo, FL

12-05-04	Section Connection American Society of Health-System Pharmacists (ASHP) 39 th Midyear Meeting Orlando, FL
11-22-04	Developing an Advanced Pharmacy Practice Model – Position in the Pharmacist to Meet the Needs of the Healthcare Marketplace National State Executives Association Meeting (NCSPAEE) Fall Symposium Marco Island, FL
10-21-04	Treatment of Pulmonary Embolus Journal Club for St. Joe's ER, Donnetello's Tampa, FL
10-17-04	To Switch or Not to Switch Brevard County Pharmacist's Association Melbourne, FL
9-26-04	Reimbursement Update Nebraska Health-System Pharmacists Association 2004 Annual Fall Seminar Mahoney State Park, NE
09-09-04	Value of Medicine Tampa Bay Association of Health Underwriters, Feather Sound Country Club Clearwater, FL
08-28-04	MMA and Reimbursement National Association of Chain Drug Stores (NACDS) 2004 Pharmacy & Technology Conference San Diego, CA
08-26-04	Pancreatic Enzymes in Malabsorption Disorders Wake AHEC Meeting Raleigh, NC
07-30-04	Value of Medicine Georgia Society of Health-System Pharmacists 2004 GSHP Summer Meeting Amelia Island, FL
07-08-04	Medicare Part D and CPT Coding Update Florida Pharmacy Association, Pfizer Marco Island, FL
04-30-04	Medicare Part D and CPT Coding Update Nova Southeastern University (NOVA) Ft. Lauderdale, FL
11-15-03	Documenting and Being Reimbursed for Care and Panel Discussion Opportunities for Pharmacists and Expanding Their Practices in Caring for Patients with Dementia, Delirium and Depression Florida Pharmacy Association Academy of Pharmacy Practice (APP) Mid-Year Clinical Conference Orlando FL

- 10-11-03 **Overview of Direct Thrombin Inhibitors**
SouthWest Florida Society of Health-System Pharmacists
2003 Annual Meeting
Professional and Therapeutic Update
Tampa, FL
- 10-11-03 **Antibiotic Treatments in the Inpatient Setting**
SouthWest Florida Society of Health-System Pharmacists
2003 Annual Meeting
Professional and Therapeutic Update
Tampa, FL
- 09-10-03 **Public Debate Forum – Pharmaceutical Importation**
Suncoast Tiger Bay Club
St. Petersburg, FL
- 06-27-03 **New Developments in the Treatment of Erectile Dysfunction
Managed Care Consultancy Panel**
Bayer Healthcare Pharmaceuticals, Sheraton City Centre Hotel,
Salt Lake Centre Hotel
Salt Lake City, UT
- 06-03-03 **Transforming Pharmacy Reimbursement – Planning Your Route:
Applying Reimbursement Strategies to diverse Practice Settings**
American Society of Health-System Pharmacists (ASHP)
Summer Meeting 2003, Learners and Leaders
San Diego, CA
- 06-02-03 **Under Construction: Obtaining Reimbursement for Clinical
Services.**
American Society of Health-System Pharmacists (ASHP)
Summer Meeting 2003, Learners and Leaders
San Diego, CA
- 05-08-03 **Treatment Options for Persistent Asthma**
Merck, Roy's Restaurant
Tampa, FL
- 04-01-03 **Roundtables in Pharmaceutical Care**
American Pharmaceutical Association (APhA)
Annual Meeting & Exposition 2003
Pharmacy Administration and Management
ACPE 202-000-03-087-L04
New Orleans, LA
- 03-31-03 **How to get paid for Pharmaceutical Care**
American Pharmaceutical Association (APhA)
Annual Meeting & Exposition 2003, Pharmacy Administration
and Management ACPE 202-000-03-040-L04
New Orleans, LA
- 03-22-03 **Pharmacy Education and Pharmacy Practice: Improving Health
Outcomes Through the Provision of Comprehensive Pharmacy
Services**
Senate Health Educational and Labor and Pension Committee
Congressional Briefing, United States Capitol, Room S-115
Washington, DC

- 03-13-03 **Peer Discussion Group TOPIC: Treatment Options for Persistent Asthma**
Merck Speaker, Del Frisco
Winter Park, FL
- 12-10-02 **Ambulatory and Chronic Care Practitioners: Development and implementation of collaborative Management plans with other providers**
American Society of Health-system Pharmacists (ASHP)
37th Annual ASHP Midyear Meeting, The ASHP Section of Home
Atlanta, GA
- 11-13-02 **Clinical Service Reimbursement Workshop**
American Society of Consultant Pharmacists (ASCP)
2002 Senior Care Pharmacy 33rd Annual Meeting and
Exhibition
Anaheim, CA
- 11-10-02 **Reimbursement for Pharmacy Services**
University of Florida, Pharmacy Law and Management
Conference 2002
Orlando, FL
- 10-05-02 **Quinolone Antibiotic Update**
Southwest Florida Society of Health-System Pharmacists
(SWFSHP)
2002 Annual Meeting, Professional and Therapeutic Update
Tampa, FL
- 09-26-02 **The Nuts and Bolts of Billing for Pharmacists' Services, Billing for Clinical Services**
Iowa Pharmacy Association
Des Moines, IA
- 07-03-02 **Fluoroquinolone Overview Lecture**
Bayer, Primary Care 2002
Kiawah Island, SC
- 06-14-02 **Toxicology and DUI**
DUI Seminar, Hillsborough County Public Defender's Office
Meeting
Tampa, FL
- 06-09-02 **Anti-Infective Treatment of Sinusitis**
Allergy, Asthma, and Immunology Associates
Key Largo, FL
- 06-07-02 **HIV Pharmacology Update**
Florida Allergy, Asthma & Immunology Society
2002 Annual Meeting
Key Largo, FL
- 02-20-02 **Insulin Delivery Devices**
Duval County Pharmacological Society, Novo Nordisk
Jacksonville, FL
- 12-13-01 **Avelox Clinical Advisory Panel**
Bayer - Stratagem Plus, Inc., Donatello's
Tampa, FL

- 12-05-01 **Public Relations: How to Get the Message Out About Today's Pharmacy Practice**
American Society of Health-System Pharmacists (ASHP)
Midyear Meeting
New Orleans, LA
- 12-04-01 **Serving as a Medical Expert Witness**
American Society of Health-System Pharmacists (ASHP)
2001 36th Annual Midyear Meeting
New Orleans, LA
- 11-18-01 **Diabetes Update: Alternative Delivery Devices**
Eckerd's Health Care
Southeastern Region Symposium
Bonita Springs, FL
- 11-06-01 **Billing for Clinical Services**
American Society of Clinical Pathologists (ASCP)
32nd Annual Meeting
Chicago, IL
- 08-09-01 **Collaboration is the Secret to Success**
Florida Society of Health-System Pharmacists (FSHP)
Annual Meeting
Orlando, FL
- 06-28-01 **FPA 111th Annual Meeting and Convention**
Marriott Marco Island Resort
Marco Island, FL
- 05-17-01 **New Drug Approvals and Research Pipelines**
Central Savannah River District of the Georgia Society of Health-System Pharmacists
Martinez, GA
- 05-16-01 **Geriatric Practice: Pharmacy Consulting Models**
American Society of Consultant Pharmacists (ASCP)
23rd Midyear Conference 2001 Geriatrics Meeting
Washington, DC
- 05-05-01 **Getting Paid for your Services**
American Society of Consultant Pharmacists (ASCP)
23rd Midyear Conference
Washington, DC
- 03-25-01 **Handheld Medical Applications**
Florida Society of Health-System Pharmacists (FSHP)
2001 Spring Meeting, Health Professions Division, Nova Southeastern University
Ft. Lauderdale, FL
- 03-01-01 **Update on Diabetes and Current Clinical Opportunities**
Association of Clinical Research Professionals (ACRP)
Suncoast Chapter
Tampa, FL
- 02-15-01 **Anti-infective Selection: The Impact Of Our Decisions**
Bayer
Tampa, FL

- 01-30-01 **Pharmacotherapy Update Insulin, Advances and Feature NovoPen 3**
Diabetes Update Lectures for Publix Pharmacists, Novo Nordisk
Orlando, FL
- 01-23-01 **Diabetes Care and Clinical Research Update**
St. Joseph's Hospital, Institutional Review Board (IRB)
Tampa, FL
- 01-23-01 **Pharmacotherapy Update Insulin, Advances and Feature NovoPen 3**
Diabetes Update Lectures for Publix Pharmacists, Novo Nordisk
Publix Divisional Office
Marietta, GA
- 01-21-01 **Pharmacotherapy Update Insulin, Advances and Feature NovoPen 3**
Diabetes Update Lectures for Publix Pharmacists, Novo Nordisk
Gainesville, FL
- 01-18-01 **Pharmacotherapy Update Insulin, Advances and Feature NovoPen 3**
Diabetes Update Lectures for Publix Pharmacists, Novo Nordisk
Tampa, FL
- 01-14-01 **Pharmacotherapy Update Insulin, Advances and Feature NovoPen 3**
Diabetes Update Lectures for Publix Pharmacists, Novo Nordisk
Deerfield Beach, FL
- 12-08-00 **Legislative Update: Pharmacy Law and Current Initiatives**
American Society of Health-System Pharmacists
Public Relations Advisory Network
Midyear Clinical Meeting
Las Vegas, NV
- 10-02-00 **Managing the Pharmacy Benefit: We Must Strive to Improve Patient Care**
Pfizer - Tri-Service Forum Regions 3 &4
Callaway Gardens, GA
- 05-26-00 **DUI Issues Training Seminar**
Hillsborough County Public Defender's Office
Tampa, FL
- 03-09-00 **Fluoroquinolone Update**
South Florida Society of Health System Pharmacists Meeting
Miami, FL
- 12-07-99 **Issues Surrounding Pharmacist Reimbursement**
American Society of Health-System Pharmacists (ASHP)
1999 Mid-Year Clinical Meeting
Orlando, FL
- 12-02-99 **Antibiotic Selection in the Age of Resistance: A Focus on Newer Agents on Selected Respiratory Tract Infections**
Bayer - CME Dinner Conference
Microbiology, Resistance and PK/PD of the Newer Agents
Dallas, TX

- 12-01-99 **Antibiotic Selection in the Age of Resistance: A Focus on Newer Agents on Selected Respiratory Tract Infections**
Bayer - CME Dinner Conference
Microbiology, Resistance and PK/PD of the Newer Agents
Houston, TX
- 11-02-99 **Antibiotic Selection in the Age of Resistance: A Focus on Newer Agents on Selected Respiratory Tract Infections**
Bayer - CME Dinner Conference
Microbiology, Resistance and PK/PD of the Newer Agents
Baton Rouge, LA
- 10-25-99 **Antibiotic Selection in the Age of Resistance: A Focus on Newer Agents on Selected Respiratory Tract Infections**
Bayer - CME Dinner Meeting
Microbiology, Resistance and PK/PD of the Newer Agents
Ft. Worth, TX
- 09-29-99 **Antibiotic Selection in the Age of Resistance: A Focus on Newer Agents on Selected Respiratory Tract Infections**
Bayer - CME Dinner Conference
Microbiology, Resistance and PK/PD of the Newer Agents
Bayer, The Pillars Restaurant
Mobile, AL
- 09-25-99 **Designing an Anticoagulation Clinic**
Saint Louis College of Pharmacy, St. Louis College of Medicine,
Fundamentals for Pharmaceutical Care Reimbursement
St. Louis, MO
- 09-23-99 **Antibiotic Selection in the Age of Resistance: A Focus on Newer Agents on Selected Respiratory Tract Infections**
Bayer - CME Dinner Conference
Microbiology, Resistance and PK/PD of the Newer Agents
Bayer, Donatello's Restaurant
Tampa, FL
- 08-13-99 **Getting Paid for Pharmaceutical Care: Guidelines for Medicaid, Medicare and Third Party Payer Reimbursement**
Pharmacy Society of Wisconsin (PSW)
1999 Annual Meeting
La Crosse, WI
- 03-05-99 **Long Term Care: Reimbursement for Clinical Services**
American Society of Consultant Pharmacists (ASCP)
North Carolina Chapter
Charlotte, NC
- 04-18-98 **Polypharmacy and the 20 Newest Drugs**
Nurse Practitioners Associates for Continuing Education
NPACE National Primary Care Conference
Orlando FL
- 03-03-98 **Advances in Quinolone Antibiotic Therapy**
Southern Gulf Society of Health-system Pharmacists
Ft. Myers, FL

- 02-24-98 **Overview of Quinolone Antibiotics: Current Market Trends**
Department of Pharmacy, St. Joseph's Hospital
Tampa, FL
- 02-20-98 **Establishing, Documenting & Marketing Clinical Services**
Clinical Practice in a Managed Care Era
22nd Annual Clinical Pharmacy Symposium
Florida A&M University School of Pharmacy
Tallahassee, FL
- 01-27-98 **Pharmaceutical Care Services in the Long Term Care Setting:
Reimbursement Strategies**
Clinical Advisory Board
Omnicare International
Cincinnati, OH
- 11-15-97 **Compensation Strategies for Hyperlipidemia Programs**
Hyperlipidemia Conference '97
Auburn University, School of Pharmacy
Auburn, AL
- 11-11-97 **Biotechnology: Pharmaceutical Care Practice Opportunities**
University of Illinois at Chicago, College of Pharmacy
Symposium on Biotechnology
Chicago, IL
- 10-18-97 **Managed Care: Drug Formulary Strategies**
Managed Care Success Strategies, Tampa Westin Hotel
Tampa, FL
- 09-27-97 **Embracing Pharmaceutical Care Practices**
Southern California Society of Health-systems Pharmacists
Los Angeles, CA
- 09-17-97 **Biotechnology: Pharmaceutical Care Practice Opportunities**
Chicago, IL
- 09-09-97 **Update on Reimbursement Strategies for Pharmaceutical Care
Services**
University of Florida Law & Management Conference
Orlando, FL
- 08-26-97 **Development of Clinical Pharmacy Services and Practice
Management Systems**
VHA Conference, Opryland Hotel
Nashville, TN
- 08-02-97 **Reimbursement Strategies for Clinical Services for Managing
Patients with Osteoporosis**
Osteoporosis Treatment Management
Mercer University
Atlanta, GA
- 07-11-97 **Asthma: Treatment and Therapeutic Alternatives**
Establishing Patient Care Services in the Pharmacy: The Basics,
CarePoint
Atlanta, GA

- 06-27-97 **Osteoporosis & Reimbursement**
Mercer University
Atlanta, GA
- 06-20-97 **Developing Advanced Practice Models for Pharmaceutical
Care Services**
Pennsylvania Society of Health-System Pharmacists
Long Branch, NJ
- 06-07-97 **Developing Reimbursement Strategies for Ambulatory Care
Services**
Nebraska Pharmacists Association
1997 Annual Convention
Grand Island, NE
- 05-17-97 **Pharmacists-based Clinical Pharmacology Research**
Florida Society of Health-Systems Pharmacists
1997 Annual Meeting
Ft. Lauderdale, FL
- 05-16-97 **Reimbursement for Pharmaceutical Care: Present and Future
Considerations**
Pharmaceutical Care A Closer Look, North Carolina Council on
Pharmaceutical Care
Chapel Hill, NC
- 05-16-97 **Marketing Pharmaceutical Care: An Essential Ingredient**
Pharmaceutical Care A Closer Look
North Carolina Council on Pharmaceutical Care
Chapel Hill, NC
- 05-10-97 **New Horizons in Diabetes Management: Reimbursement
Models**
New Jersey Society of Certified Diabetes Education
Diabetes Educators Symposium
Voorhees, NJ
- 05-03-97 **Practice models for service and reimbursement – Diabetes
Management**
Metro New York – Garden State Diabetes Educators
Symposium
West Orange, NJ
- 05-01-97 **Evaluation Methods for Clinical Pharmacology Trials**
University of South Florida, Department of Pediatrics
Residents Program
Tampa, FL
- 04-29-97 **Tinnitus: Treatment and Management Update**
American Tinnitus Association
Tampa Bay Chapter/Support Group
Tampa, FL
- 04-22-97 **Clinical Pharmacology Review: American Board of Internal
Medicine Review Course**
University of South Florida College of Medicine
Medical Residents
Tampa, FL

- 04-12-97 **Advanced Practice Models: The Future of Pharmaceutical Care**
Louisiana Society of Health-System Pharmacists
New Orleans, LA

- 04-04-97 **New Treatments for HIV: Update**
National Association of Nurse Practitioner's Conference
1997 NPACE
Orlando, FL

- 04-04-97 **Top 20 New Medications**
National Association of Nurse Practitioner's Conference
1997 NPACE
Orlando, FL

- 04-04-97 **Antibiotic Update: 1997**
National Association of Nurse Practitioner's Conference
1997 NPACE
Orlando, FL

- 03-15-97 **Advanced Practice Models for Pharmaceutical Care**
South Florida Society of Health-System Pharmacists
Miami, FL

- 03-09-97 **Developing Reimbursement Strategies for Clinical Pharmacy Services**
Greensboro AHEC
Greensboro, NC

- 03-07-97 **Getting Paid for Pharmaceutical Care: Reimbursement Workshop**
American Pharmaceutical Association (APhA)
1997 Annual Meeting
Los Angeles, CA

- 12-12-96 **Cost Impact of Lipid Lowering Therapy**
Managed Care Medical Directors of Florida
1996 Annual Meeting
Tampa, FL

- 09-14-96 **Management of Tuberculosis: Clinical Case Studies**
Southwest Florida Society of Health system Pharmacists (SWFSHP)
1996 Annual Meeting
Update on the Management of Infectious Diseases
Tampa, FL

- 11-07-96 **Value of Pharmaceutical Disease Management in Reducing Overall Health Care Costs**
Merck - Central Florida Health Care Coalition (CFHCC)
Orlando, FL

- 08-17-96 **Management and New Therapies for HIV Infection**
Update on HIV and Related Infections
A Continuing Education Program for Pharmacists
University of South Florida
Tampa FL

- 04-08-96 **Implementation of Community Based Pharmaceutical Care Service**
Florida Society of Health-System Pharmacists Midyear Meeting
Ft. Lauderdale, FL

- 03-26-96 **Newer Antibiotics in the Managed Care Setting**
Challenges in Pharmaceutical Care
Braintree, MA

- 02-22-96 **Pharmacokinetic Services: Pharmacist Managed Consult Service Model**
Polk County Pharmaceutical Association
Bartow, FL

- 02-10-96 **Pharmacoeconomic Trials: Designing Research Trials to Improve Clinical Outcomes and Reduce Health Care Costs**
United States Pharmacoeconomic Advisory Board, Bayer
Vail, CO

- 11-07-95 **Value of Pharmaceutical Disease Management In Reducing Overall Health Care Costs Reducing Overall Health Care Costs Through Pharmaceutical and Disease Intervention,**
The Healthcare Revolution, Central Florida Health Care Coalition (CFHCC)
Orlando, FL

- 10-04-95 **Pharmacy Management Course**
University of Florida
Gainesville, FL

- 10-01-95 **Applying Reimbursement Coding to Pharmaceutical Care Services**
New York State Council of Health-System Pharmacists
1995 Annual Meeting
Newburgh, NY

- 09-16-95 **Pharmacists Care of Anticoagulant and Cardiovascular Patients**
Florida Pharmacy Association Continuing Education Series
St. Petersburg, FL

- 08-26-95 **Practical Issues Related to the Conduct of Clinical Trials, Research & Development: Oral Streptogramins In Sinusitis**
Four Seasons Hotel
Chicago, IL

- 08-15-95 **Expanding Services in the Diabetes Marketplace**
Orange County Pharmaceutical Association
Orlando, FL

- 08-07-95 **Macrolide Antibiotic Update**
American College of Clinical Pharmacy
1995 Annual Meeting
Washington, DC

- 08-04-95 **Pharmaceutical Care: Nephrology Services, Developing Reimbursement Strategies**
Florida Society of Health-system Pharmacist
1995 Annual Meeting, Stouffer Hotel
Orlando, FL

- 08-04-95 **Justification of Pharmacy Services: Survival for the Future, Panel Discussion**
Opening Session, Florida Society of Health-system Pharmacist
1995 Annual Meeting, Stouffer, Hotel
Orlando, FL
- 07-25-95 **Implementing Pharmaceutical Care**
Practitioner Panel Tennessee Pharmacist Association 108th
Annual Meeting
Memphis, TN
- 06-06-95 **Expanding Pharmaceutical Care in and Era of Declining Resources**
American Society of Hospital Pharmacists
1995 Annual Meeting
Philadelphia, PA
- 05-21-95 **Issues in Infectious Diseases: 1995**
CE on the SEA, Continuing Education Seminar
Ocho Rios, Jamaica
- 05-19-95 **Antibiotic Update: 1995**
Florida Nurses Association, Belleview Biltmore
Clearwater, FL
- 05-16-95 **Update on Antifungal Therapy: Primer for Clinical Practice**
Pinellas County Pharmaceutical Association
Pinellas Park, FL
- 05-10-95 **Steroid Overview for Primary Care Practice**
Nurse Practitioner Association for Continuing Education
1995 Annual Meeting
Orlando, FL
- 04-18-95 **Pharmaceutical Care: Intensive Insulin Therapy**
Southern Gulf Society of Hospital Pharmacist, Holiday Inn
Ft. Myers, FL
- 04-08-95 **Pharmacotherapeutic Care Plans for Ambulatory Patients**
Implementation of Community Based Pharmaceutical Care
Service
Ft. Lauderdale, FL
- 04-08-95 **Developing a Nephrology Pharmaceutical Care Practice**
Florida Society of Hospital Pharmacist
1995 Annual Meeting
Ft. Lauderdale, FL
- 04-07-95 **Issues and Advances in Pediatrics. Advances in Pediatric Pharmacology: Medications and Drug Delivery Systems**
Sheraton Sand Key Resort
Clearwater Beach, FL
- 03-21-95 **Reimbursement for Pharmaceutical Care Services**
Southern Gulf Society of Hospital Pharmacist
Lee Memorial Hospital
Ft. Myers, FL

- 02-16-95 **Early Presumptive Antifungal Therapy**
Internal Medicine Grand Rounds, University of South Florida
College of Medicine
Tampa, FL
- 02-24-95 **Aminoglycoside and Vancomycin Pharmacokinetics: Clinical Application**
Course# PHA4123/5121, University of Florida, College of
Pharmacy
Gainesville, FL
- 02-25-95 **Pediatric Hyperlipidemia: Assessment and Management**
University of Florida College of Pharmacy
Post Graduate PharmD. Program, USF College of Public Health
Tampa, FL
- 02-04-95 **New Approaches to Cancer Therapy: Gene Therapy and Monoclonal Antibodies**
Florida Pharmacy Association
Academy of Pharmacy Practice
Clinical Mid-Year Conference
Orlando, FL
- 01-27-95 **Reimbursement Factors in Modern Healthcare**
Miles 1995 Pharmacy Advisory Board
Innisbrook, FL
- 01-28-94 **Pharmaceutical Care and Reimbursement for Pharmacy Services**
Miles Pharmacy Advisory Group
Tarpon Springs, FL
- 12-13-94 **Establishing Reimbursement Guidelines for Cognitive Services**
North Pinellas Pharmacy Association
Tarpon Springs, FL
- 12-05-94 **Issues in Antifungal Therapy**
American Society of Hospital Pharmacists
Exhibitor's Theater Program
29th Midyear Clinical Meeting, Miami Beach Convention
Center
Miami, FL
- 11-19-94 **Clinical Aspects of Early Antifungal Therapy in the ICU**
Cost Effectiveness in the ICU
Orlando Hilton
Orlando, FL
- 11-10-94 **Review of Antifungal Therapy**
Mobile Pharmacy Association, Providence Hospital
Mobile, AL
- 10-18-94 **Diabetes and the Geriatric Patient**
VA Medical Center
Miami, FL

- 10-07-94 **Medications and Their Impact on Ototoxicity and Patient Assessment**
Florida Speech and Hearing Association
1994 Annual Meeting
Cocoa Beach, FL
- 10-06-94 **Contribution of Biotechnology to Pharmaceutical Pipelines: Current and Future**
American College of Clinical Pharmacology, Symposium
23rd Annual Meeting
Orlando, FL
- 08-05-94 **Obtaining Reimbursement for Therapeutic Outcomes Monitoring**
TOM Pharmacist Meeting
University of Florida College of Pharmacy
Gainesville, FL
- 08-04-94 **Considerations in the Diagnosis and Treatment of Fungal Infections**
National Teleconference, American Teleconferencing
Tampa, FL
- 08-04-94 **A Pharmacotherapeutic Care Plan Model: Renal Disease, Pharmacoeconomic Considerations II**
Florida Society of Health system Pharmacists
1995 Annual Meeting
Orlando, FL
- 08-04-94 **Financial Impact of Innovative Pharmaceutical Services**
Florida Society of Health system Pharmacists
Opening General Session: Forces Affecting Health Care in Florida
1995 Annual Meeting
Orlando, FL
- 07-08-94 **Reimbursement for Pharmacy Services**
Arizona Society of Hospital Pharmacists
1994 Annual Meeting
Tucson, AZ
- 06-22-94 **Antifungal Therapy: Clinical Software Applications**
Pharmacy Grand Rounds, Gunnersville Hospital
Gunnersville, AL
- 06-21-94 **Antifungal Therapy: Clinical Software Applications**
University Hospital Pharmacists
Birmingham, AL
- 06-20-94 **Rational Antifungal Therapy in Hospitalized Patients**
Grand Rounds, Lakeland Regional Hospital
Lakeland, FL
- 06-08-94 **Pain Management and Non-steroidal Anti-inflammatory Agents**
Pain Management Symposium, Tampa General Hospital
Tampa, FL

- 06-07-94 **Maximizing Reimbursement for Pharmaceutical Products and Services**
American Society of Hospital Pharmacists, Exhibitor's Theater,
51st Annual Meeting
Reno, NV

- 05-05-94 **The Rising Cost of Candida Infections**
Northwest Alabama Pharmacists Association
Florence, AL

- 04-08-94 **Antifungal Therapy in the Critically Ill**
American Association of Critical Care Nurses Gulf coast
Chapter Spring Meeting

- 03-26-94 **Reimbursement Guidelines for Pharmacy Services**
Pharmaceutical Care Forum, CarePoint
Folly Beach, SC

- 03-06-94 **Health Care Reform: Preparing Pharmacy for Change**
Tennessee Society for Hospital Pharmacist
1994 Annual Meeting
Nashville, TN

- 02-25-94 **Patient Education and Pharmaceutical Care**
1994 Update: Colony Stimulating Factors
St. Petersburg, FL

- 02-15-94 **Opportunities for Pharmacists in Biotechnology**
West Alabama Society of Hospital Pharmacists
Tuscaloosa, AL

- 02-10-94 **Health care Reform: It's Impact on Pharmacy Practice**
Society of Hospital Pharmacists
Tallahassee, FL

- 02-05-94 **Patient Monitoring - Software Applications**
Cytokine Forum Group
San Diego, CA

- 02-04-94 **Developing Reimbursement Guidelines of Pharmaceutical Care Services**
CarePoint Pharmaceutical Care Conference
Atlanta, GA

- 01-28-94 **Pharmaceutical Care and Reimbursement for Pharmacy Services**
Miles Pharmacy Advisory Group
Tarpon Springs, FL

- 01-13-94 **Implementing System for Payment**
An update on OBRA 90
The 22nd Annual Pharmacy Law and Management
Conference
Lake Buena Vista, FL

- 12-09-93 **New Clinical Software Applications**
American Society of Hospital Pharmacists
1993 Midyear Clinical Meeting
Atlanta, GA

- 12-09-93 **Clinical Case Studies: Antifungal Therapy**
American Society of Hospital Pharmacists
1993 Midyear Clinical Meeting
Atlanta, GA
- 12-08-93 **Health Care Reform: It's Impact on Hospitals and Pharmacy, How Hospital Pharmacy Will Be Affected**
American Society of Hospital Pharmacists
1993 Midyear Clinical Meeting
Atlanta, GA
- 11-21-93 **Biotechnology Pharmaceutical Products: The Pharmacists Role**
South Dakota Pharmaceutical Association
1993 Annual Meeting
Sioux Falls, SD
- 11-13-93 **Implementing a System for Payment**
University of Florida College of Pharmacy
22nd Annual Pharmacy Law and Management Conference,
"An Update of OBRA 90"
Gainesville, FL
- 11-12-93 **The Diabetes Marketplace**
Gulf Coast Pharmaceutical Association
Ft. Meyers, FL
- 11-07-93 **Pharmacoeconomics and Colony Stimulating Factors**
Georgia Society of Hospital Pharmacists
Thomasville, GA
- 10-03-93 **Reimbursement for Patient Consultation**
Illinois Pharmacists Association
113th Annual Meeting and Exhibition
Rockford, IL
- 09-26-93 **Insulin & Diabetes Update**
Southeastern Society of Hospital Pharmacists
Ft. Lauderdale, FL
- 09-14-93 **Update on Health Care Reform**
Eastern Shores Florida Society of Hospital Pharmacists
Daytona, FL
- 08-22-93 **Experiences with Utilization of CPT Coding Reimbursement for Clinical Services: Round Table Forum**
Florida Society of Hospital Pharmacists
1993 Annual Meeting
Orlando, FL
- 08-19-93 **Managing Patients on Biologic Response Modifiers Practical Applications of Biologic Response Modifiers**
Florida Society of Hospital Pharmacists
1993 Midyear Meeting
Orlando, FL
- 08-14-93 **Leadership Skills: Tricks of the Trade**
Florida A&M Leadership Conference
Orlando, FL

- 07-13-93 **The Pharmacoeconomics of Antifungal Therapy**
Vanderbilt University, Department of Pharmacy
Nashville, TN
- 07-10-93 **Pharmaceutical Biotechnology Update**
ALCO Health Services Corporation
1993 Annual Meeting
Orlando, FL
- 06-24-93 **Important Issues in the Selection of IV versus PO Fluconazole**
Teleconference Pfizer Pharmaceuticals
- 06-22-93 **Insulin Update**
Hillsborough County Pharmaceutical Association
Tampa, FL
- 06-10-93 **Important Issues in the Selection of IV versus PO Fluconazole**
Teleconference Pfizer Pharmaceuticals
Tampa, FL
- 06-07-93 **Amlodipine and Beta Blockers**
American Society of Hospital Pharmacists
1993 Annual Meeting
Denver, CO
- 05-30-93 **Developing Reimbursement Strategies for Clinical Services**
Florida A&M University
Clearwater, FL
- 05-25-93 **Monitoring Patients on Biologic Response Modifiers**
National Home Infusion Association/National Association of
Retail Druggist
1993 Annual Meeting, Rx Expo '93
Orlando, FL
- 05-21-93 **Clinical Pharmacokinetic Software**
University of Florida, Applied Pharmacokinetics 1993
Gainesville, FL
- 05-19-93 **Important Issues in the Selection of IV versus PO Fluconazole**
Teleconference Pfizer Pharmaceuticals
Tampa, FL
- 05-13-93 **Important Issues in the Selection of IV versus PO Fluconazole**
Capital Society of Hospital Pharmacists
Tallahassee, FL
- 05-07-93 **Important Issues in the Selection of IV versus PO Fluconazole**
Flagler Community Hospital, Department of Pharmacy
St. Augustine, FL
- 05-07-93 **Important Issues in the Selection of IV versus PO Fluconazole**
St. Vincent's Hospital, Department of Pharmacy
Jacksonville, FL
- 05-01-93 **Drug Research and Development: From the Laboratory to the
Drug Store**
Cystic Fibrosis Family Day, University of South Florida,
Department of Pediatrics
Tampa, FL

04-29-93	Important Issues in the Selection of IV versus PO Fluconazole Teleconference Pfizer Pharmaceuticals Tampa, FL
04-28-93	Important Issues in the Selection of IV versus PO Fluconazole Birmingham Hospital Pharmacists Program Birmingham, AL
04-27-93	Important Issues in the Selection of IV versus PO Fluconazole Montgomery Regional Hospital Pharmacists, Penach at Rose Hill Montgomery, AL
04-23-93	Pharmaceutical Biotechnology Update American Association Critical Care Nurses 1993 Annual Meeting Clearwater, FL
04-22-93	Pharmaceutical Biotechnology: Research and Development Anderson Memorial Hospital, Medical Grand Rounds Anderson, SC
04-07-93	Important Issues in the Selection of IV versus PO Fluconazole Teleconference Pfizer Pharmaceuticals Tampa, FL
02-24-93	Important Issues in the Selection of IV versus PO Fluconazole Teleconference Pfizer Pharmaceuticals Tampa, FL
02-18-93	Therapeutic Drug Monitoring: Antibiotics University of Florida, College of Pharmacy Pharmacokinetics Course Gainesville, FL
12-28-92	JCAHO and Home Health Care CareStat of Colorado, Department of Pharmacy Denver, CO
12-15-92	Selection of IV versus PO Fluconazole Therapy Teleconference Tampa, FL
12-13-92	Reimbursement for Clinical Pharmacy Services Florida Pharmaceutical Association Sarasota, FL
11-21-92	Reimbursement for Clinical Pharmacy Services "Implementing OBRA '90" Twenty-First Annual Pharmacy Law and Management Conference Orlando, FL
11-20-92	Pharmacy Practice in the 1990's Seminole Heights Elementary School, Great American Teach-In Tampa, FL

- 10-24-92 **New Medications and Absorption Routes - How They Can Interact**
Florida Nurses Association
Third Annual Pharmacology Update
Tampa, FL

- 10-14-92 **Drug Utilization Review and Outcomes Management**
Georgia Shared Services, Fall Forum 1992
Callaway, GA

- 10-07-92 **Pharmacological Approach to the Treatment of Pressure Ulcers**
Pressure Ulcers - Prevention, Assessment, Treatment and Infection Control
Sand Key Beach, FL

- 09-30-92 **Review of Antifungal Therapy**
Pfizer Pharmaceuticals, Southeastern Regional Sales Division
Regional Sales Meeting
Tampa, FL

- 09-15-92 **Advances in Oral Antibiotics**
Augusta Pharmaceutical Association
Augusta, GA

- 09-06-92 **Biotechnology and Immunology**
Puerto Rico Pharmaceutical Association
San Juan, Puerto Rico

- 08-14-92 **Biotechnology and Drug Development**
Pharmacy Grand Rounds
HCA Community Hospital
New Port Richey, FL

- 08-13-92 **Review of Amphotericin B and Antifungal Therapy**
Roche Professional Services Division
Home Health Pharmacy Services
Tampa, FL

- 07-27-92 **Advances in Biotechnology and Drug Development**
Pharmacy Grand Rounds, St. Joseph's Hospital
Tampa, FL

- 07-18-92 **Application of Biotechnology in Medicine**
Florida Pharmaceutical Association, Annual Meeting 1992,
Boca Raton, FL

- 07-14-92 **Advances in Hospital Pharmacy Practice**
Pharmaceutical Training Seminar, Miles, Inc.
Orlando, FL

- 05-20-92 **Health Care Reform: Impact on Pharmacy Services**
Eastern Shores Society of Hospital Pharmacists
Daytona Beach, FL

- 05-15-92 **All Americas Health care Conference**
AIDS Update, Moderator
Tampa, FL

- 04-16-92 **Antimicrobial Testing and Resistance**
Memorial Hospital (AMI)
Tampa, FL

- 04-14-92 **Clinical Pharmacology Review or Sertraline**
Hillsborough County Pharmaceutical Association
Tampa, FL
- 04-02-92 **Monoclonal Antibodies and Antibiotic Selection**
Pinellas County Hospital Pharmacists
Clearwater, FL
- 03-25-92 **Monoclonal Antibodies: Clinical Applications**
Health care Forum, Regional Hospital Consortium
Miami, FL
- 03-11-92 **Biotechnology in Retail Pharmacy**
Pasco/Hernando County Pharmaceutical Association
New Port Richey, FL
- 03-05-92 **Introduction to Use and Handling of Biotechnology Agents**
Ohio Society of Hospital Pharmacists, "Pharmacy Technician
Program"
1992 Annual Meeting
Dayton, OH
- 02-27-92 **Introduction to Clinical Pharmacology Principles**
University of South Florida, Internal Medicine Noon Conference
Tampa, FL
- 02-05-92 **Therapeutic Drug Monitoring in Psychiatry**
University of South Florida, Psychiatry Residence Conference
Tampa, FL
- 01-15-92 **Analysis of Antibiotic Selection and Treatment on the Clinical
Outcome of Monoclonal Anti-Endotoxin Therapy**
Merck Research Laboratories
Rahway, NJ
- 12-10-91 **Profile of the Clinical Pharmacokinetic Software Marketplace**
Syva International, Marketing Division
Tampa, FL
- 12-05-91 **Selecting Clinical Pharmacokinetic Software**
American Society of Hospital Pharmacists
1991 Midyear Clinical Meeting
New Orleans, LA
- 12-01-91 **Clinical Applications for Colony Stimulating Factors**
Long Island Hospital Pharmacy Directors Meeting
Long Island, NY
- 09-29-91 **Clinical Documentation: Important or Impractical?**
Indian River Pharmacy Association
Vero Beach, FL
- 08-10-91 **Colony Stimulating Factors: From Laboratory to Clinical
Applications**
Southern Gulf Society of Hospital Pharmacist
Ft. Myers, FL
- 08-08-91 **Medical Legal Issues in Pharmacy Practice**
Moderator Current Issues in Pharmacy Practice
Lake Buena Vista, FL

- 06-07-91 **Colony Stimulating Factors: Clinical Applications**
Southeastern Society of Hospital Pharmacists
North Broward Medical Center
Ft. Lauderdale, FL
- 05-16-91 **Colony Stimulating Factors: From Laboratory to Clinical Applications**
Polk County Pharmacy Association
Lakeland, FL
- 04-26-91 **Evaluation of Clinical Services: Outcomes Management**
Moses H. Cone Hospital, Pharmacy Grand Rounds
Greensboro, NC
- 04-06-91 **Clinical Impact of Nutrition Support in Home Health care**
Roche Professional Services, Clinical Training Program
Tampa, FL
- 03-15-91 **Therapeutic Drug Monitoring: Applications in Home Health care**
Dun & Bradstreet Corporation
Tampa, FL
- 01-26-91 **Pharmacology Concerns for the Audiologist**
Florida Association of Speech, Hearing, and Audiology
(FLASHA) Winter Conference
Gainesville, FL
- 01-91 **Drug-Induced Ototoxicity**
Florida Language Speech and Hearing Association
1991 Winter Meeting
Cocoa Beach, FL
- 11-90 **Clinical Outcomes Management**
Southwest Florida Society of Hospital Pharmacists
1990 Annual Meeting
St. Petersburg, FL
- 08-90 **Clinical Pharmacokinetics: Software Review**
Florida Society of Hospital Pharmacists
24th Annual Meeting
Orlando, FL
- 06-90 **Outcomes Management**
Southwest Central Louisiana Society of Hospital Pharmacists
Baton Rouge, LA
- 05-90 **Anti-infective Therapy in the Immunocompromised Patient**
Orlando Pharmacy Symposium '90, Co-Chairman
Orlando, FL
- 10-89 **Review of Clinical Pharmacokinetic Software**
California Society of Hospital Pharmacists Seminar
1989 Meeting
Los Angeles, CA
- 10-89 **Evaluation of Commercially Available Pharmacokinetic Software Systems**
Georgia Society of Hospital Pharmacists Midyear Meeting
Athens, GA

- 10-89 **Bayesian Pharmacokinetics**
Pharmacy Grand Rounds, H. Lee Moffitt Cancer Center
Tampa, FL
- 02-89 **Clinical Pharmacokinetics Software Systems**
Pharmacy Grand Rounds, H. Lee Moffitt Cancer Center
Tampa, FL
- 04-88 **Design and Implementation of a Computerized
Pharmacokinetic Patient Tracking System**
Southeastern Residents Conference
Athens, GA
- 10-87 **Geriatric Pharmacology: Therapeutic Considerations**
Emory University Hospital, Pharmacy Grand Rounds
Atlanta, GA
- 11-86 **Aminoglycoside Dosing Adjustments in Renal Failure**
Emory University Hospital, Clinical Pharmacy Department
Atlanta, GA
- 08-86 **Vaccinating the Elderly**
Veteran's Administration Hospital, Medical Staff
Atlanta, GA
- 06-86 **Pneumocystis carinii Pneumonia in AIDS Patients: Current
Treatments and Investigational Agents**
DeKalb General Hospital, Clinical Pharmacy Department
Atlanta, GA
- 11-85 **The Pharmacological Interactions of Lithium Carbonate**
Georgia Mental Health Institute, Medical Staff Conference
Atlanta, GA
- 11-85 **Clinical Case Study: Organic Personality Syndrome**
Georgia Mental Health Institute, Medical Staff Conference
Atlanta, GA

TELEVISION / RADIO / MEDIA:

- 05-01-13 **Transitional Care CPT Codes May Include Pharmacists' Services**
Pharmacy News
Kate Traynor
- 09-11-12 **Connecting Health: Medication Therapy Management**
Medical Update Show
Jacksonville, FL
- 01-14-10 **Antidepressants Can Lead to Weight Gain**
St. Petersburg Times
Irene Maher
- 10-09 **Current Concepts in Pharmacy Management: Medicare Part D**
Interview
David's Production, Inc.
- 07-09-09 **United States Health Care Reform 2009**
Drive Time with Bill Bunkley, WTBN
William Bunkley

07-09	Viagra – Video Taped Interview Posted on website
06-24-09	Increased abuse of synthetic medications BBC World News: World Service George Arney
08-18-08	Opiate Toxicity Dr. G Medical Examiner Show Discovery Health
10 – 07	Front-line Practitioners Offer Keys To Their Success Pharmacy Today Page 36
07-21-07	Tampabay.com Know it now An Hour of Expert Witness Time, \$4,000 Interview with Scott Barancikn
06-01-06	Pharmacist Current Procedural Terminology Codes and Medication Therapy Management American Journal of Health-System Pharmacists Volume 63, Page 1008 & 1010
05-09-06	Medicare Part D: The Facts about the May 15th Deadline for Signing up Drive Time, WTBM AM 570/910, News Radio
04-12-06	Medicare Part D: Selecting the Plan That Meets Your Needs Drive Time, WTBM AM 570/910, News Radio
09-07-05	Linda Hurtado, Channel 28
07-19-05	Medication Importation and Risk of Fatal Toxicities Dr. G Medical Examiner (Jan C. Garavaglia, MD) Discovery Health Channel
07-13-05	Post Partum Depression Channel 13, WTVT/FOX, Kathy Fountain Show, Tampa, FL
05-01-05	Distinguished Achievement Award in Clinical/Pharmacotherapeutic Practice APhA – APPM awardees to be recognized APhA2005 Annual Meeting News
01-25-05	Jeff Fisher (WFLA-AM) Interview Tampa, FL
02-24-04	Violence In ‘Passion’ Necessary, Viewers Say The Tampa Tribune, Metro, Philip Morgan
02-01-04	APhA Member Goes to Bat for Pharmacy Pharmacy Today, Volume 10, Number 2
12-03	People Talk - Daniel E. Buffington, PharmD, MBA a Member of The X12 Panel Computer Talk, Volume 23, Number 6, November/December 2003, Page 51

06-03	What You Can Do: Tips for Telling Your Story ASHP Action Line, Special Edition, The American Society of Health-System Pharmacists, Monthly New Bulletin, Volume 33, Number 3
01-03	Beyond dispensing and drug therapy management: Pharmacist creates a medical specialty practice model APHA Pharmacy Today, Volume 9, Number 1, January 2003, Pages 14-15, 18
01-10-02	Experts: Safe overall, drug demands caution St. Petersburg Times, Newspaper
06-20-01	Oxycontin Channel 62, WVEA-TV (Entravision), Evening News, Tampa, FL
10-06-00	Drug Pricing Channel 8, WFLA, Evening News, Tampa, FL
Summer 2000	Innovative Pharmacology Practice Decreases Healthcare Costs Health & Medical Feeling Good, Summer 2000, Page 27-28
02-09-98	Golf Max CBS Channel 10, WTSP, Evening News, Tampa, FL
01-30-98	Cleaning Out Your Medicine Cabinet Channel 8, WFLA, Evening News, Tampa, FL
10-13-97	Nutritional Supplements: Trends in Alternatives to Prescription Medications Channel 10, WTSP/ACB, Evening News, Tampa, FL
06-30-97	Non-prescription Products for Relief of Alcohol Related Hangovers Channel 10, WTSP/ACB, Evening News, Tampa, FL
06-18-97	Caffeine Containing Soft Drinks and their Impact on Your Health Channel 8 WFLA, NBC Evening News, Tampa, FL
04-28-97	Understanding Prescription Medication Pricing Channel 10, WTSP/ABC News, Tampa, FL
02-25-97	Oral Contraceptives: Morning After Pills? Channel 8, WFLA, NBC Evening News, Tampa, FL
01-28-97	Breast Pill Channel 10, WTSP News, Tampa, FL
11-28-96	Diabetes: Understanding New Drug Therapies Channel 28, WFTS/ABC, Evening News Tampa, FL

- 11-11-96 **Medications which may cause weight gain**
Channel 8, WFLA, NBC Evening News,
Tampa, FL
- 11-05-96 **Nutritional Supplements for Sports & Fitness: Helpful or Harmful**
Channel 28, WFTS/ABC, Evening News,
Tampa, FL
- 09-23-96 **HIV Treatment Update: Salk/Remune Vaccine**
Channel 13, WTVT/FOX, Good Morning Tampa Bay,
Tampa, FL
- 09-13-96 **Dr. On Call, What is Remune?**
Channel 13,
Tampa, FL
- 09-09-96 **New Experimental Vaccine Therapy for HIV**
Channel 8, WFLA/NBC, Evening News,
Tampa, FL
- 1996 **Clinical Pharmacology Services – Medication Consulting & Clinical Research**
Feeling Good, Premiere Issue 1996, Page 39
- 08-29-96 **Developing New Treatments for HIV & AIDS Infection**
Channel 8, WFLA, NBC Evening News,
Tampa, FL
- 02-07-96 **Smoking Cessation: Using Injectable Medications**
Channel 8, WFLA/NBC, Evening News,
Tampa, FL
- 11-07-95 **Analgesics**
Channel 13,
Tampa, FL
- 10-10-95 **Medications in the Treatment of Obesity**
Channel 13 WTVT, Evening News,
Tampa, FL
- 09-14-95 **Non-approved use of prescription medications: Misoprostol and Methotrexate**
Channel 13, WTVT, FOX, Evening News,
Tampa, FL
- 08-24-95 **Medications in the Elderly: United States General Accounting Office 1995 Report**
Channel 13, WTVT, FOX, Good Morning Tampa Bay,
Tampa, FL
- 08-23-95 **GATT Treaty and it's Impact on Pharmaceutical Patents and Pricing**
National Public Radio (NPR), WUSF 90 FM,
Tampa, FL
- 07-27-95 **Prescription to over-the-counter antacid preparations**
Channel 13, WTVT/FOX, Good Morning Tampa Bay,
Tampa, FL

06-13-95	Diet Pills and Weight Loss Channel 13, WTVT/CBS, Evening News Tampa, FL,
02-22-95	Overmedication in The Elderly Channel 8, WFLA/NBC News, Evening News, Tampa, FL
11-01-94	Awards and Installation Banquet, FSHP Forerunner Award The Florida Journal of Hospital Pharmacy, Volume 14 Number 5,
05-19-94	Medical Charity Concert - Band Side FX Channel 8, WFLA, NBC, Evening News, Tampa, FL
05-04-94	Antibiotic Resistance Channel 8, WFLA, NBC, Evening News, Tampa, FL
04-13-94	Toxic Effects of Tobacco and Solvents Used in the Production of Cigarettes Channel 10, WTSP, ABC, Evening News, Tampa, FL
02-15-94	Health Tips: Medication Awareness and Counseling Channel 8, WFLA, NBC, Evening News, Tampa, FL
06-30-93	Cow's Head Pills: Asian Herbal Medications Channel 13, WTVT, CBS, Morning News, Tampa, FL
03-25-93	New Medical Uses for Aspirin Channel 8, WFLA, NBC, Morning News Tampa, FL